<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="review-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Front Immunol</journal-id><journal-id journal-id-type="iso-abbrev">Front Immunol</journal-id><journal-id journal-id-type="pmc-domain-id">1754</journal-id><journal-id journal-id-type="pmc-domain">frontimmu</journal-id><journal-id journal-id-type="publisher-id">Front. Immunol.</journal-id><journal-title-group><journal-title>Frontiers in Immunology</journal-title></journal-title-group><issn pub-type="epub">1664-3224</issn><publisher><publisher-name>Frontiers Media SA</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10141304</article-id><article-id pub-id-type="pmcid-ver">PMC10141304.1</article-id><article-id pub-id-type="pmcaid">10141304</article-id><article-id pub-id-type="pmcaiid">10141304</article-id><article-id pub-id-type="pmid">37122743</article-id><article-id pub-id-type="doi">10.3389/fimmu.2023.1139554</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Immunology</subject><subj-group><subject>Review</subject></subj-group></subj-group></article-categories><title-group><article-title>The shaping of gut immunity in cirrhosis</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Mu&#241;oz</surname><given-names initials="L">Leticia</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/1659151"/></contrib><contrib contrib-type="author"><name name-style="western"><surname>Caparr&#243;s</surname><given-names initials="E">Esther</given-names></name><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/644664"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Albillos</surname><given-names initials="A">Agust&#237;n</given-names></name><xref rid="aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff5" ref-type="aff">
<sup>5</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/636223"/></contrib><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Franc&#233;s</surname><given-names initials="R">Rub&#233;n</given-names></name><xref rid="aff2" ref-type="aff">
<sup>2</sup>
</xref><xref rid="aff3" ref-type="aff">
<sup>3</sup>
</xref><xref rid="aff4" ref-type="aff">
<sup>4</sup>
</xref><xref rid="aff6" ref-type="aff">
<sup>6</sup>
</xref><xref rid="fn001" ref-type="author-notes">
<sup>*</sup>
</xref><uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://loop.frontiersin.org/people/29108"/></contrib></contrib-group><aff id="aff1">
<sup>1</sup>
<institution>Departamento de Medicina y Especialidades M&#233;dicas, Universidad de Alcal&#225;, Alcal&#225; de Henares</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff><aff id="aff2">
<sup>2</sup>
<institution>Centro de Investigaci&#243;n Biom&#233;dica en Red de Enfermedades Hep&#225;ticas y Digestivas (CIBERehd), Instituto de Salud Carlos III</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff><aff id="aff3">
<sup>3</sup>
<institution>Grupo de Inmunobiolog&#237;a Hep&#225;tica e Intestinal, Departamento Medicina Cl&#237;nica, Universidad Miguel Hern&#225;ndez</institution>, <addr-line>San Juan</addr-line>, <country>Spain</country>
</aff><aff id="aff4">
<sup>4</sup>
<institution>Instituto de Investigaci&#243;n Sanitaria ISABIAL, Hospital General Universitario de Alicante</institution>, <addr-line>Alicante</addr-line>, <country>Spain</country>
</aff><aff id="aff5">
<sup>5</sup>
<institution>Departamento de Gastroenterolog&#237;a y Hepatolog&#237;a, Hospital Universitario Ram&#243;n y Cajal, Instituto Ram&#243;n y Cajal de Investigaci&#243;n Sanitaria (IRYCIS)</institution>, <addr-line>Madrid</addr-line>, <country>Spain</country>
</aff><aff id="aff6">
<sup>6</sup>
<institution>Instituto de Investigaci&#243;n, Desarrollo e Innovaci&#243;n en Biotecnologi&#237;a Sanitaria de Elche (IDiBE), Universidad Miguel Hern&#225;ndez</institution>, <addr-line>Elche</addr-line>, <country>Spain</country>
</aff><author-notes><fn fn-type="edited-by"><p>Edited by: Javier Leceta, Complutense University of Madrid, Spain</p></fn><fn fn-type="edited-by"><p>Reviewed by: Ian Cartwright, University of Colorado Anschutz Medical Campus, United States; Xiaomin Yao, Grossman School of Medicine, New York University, United States</p></fn><corresp id="fn001">*Correspondence: Agust&#237;n Albillos, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:agustin.albillos@uah.es">agustin.albillos@uah.es</email>; Rub&#233;n Frances, <email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mailto:rfrances@umh.es">rfrances@umh.es</email></corresp><fn fn-type="other" id="fn002"><p>This article was submitted to Mucosal Immunity, a section of the journal Frontiers in Immunology</p></fn></author-notes><pub-date pub-type="epub"><day>14</day><month>4</month><year>2023</year></pub-date><pub-date pub-type="collection"><year>2023</year></pub-date><volume>14</volume><issue-id pub-id-type="pmc-issue-id">427662</issue-id><elocation-id>1139554</elocation-id><history><date date-type="received"><day>07</day><month>1</month><year>2023</year></date><date date-type="accepted"><day>27</day><month>3</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>01</day><month>01</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>29</day><month>04</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-05-01 11:26:21.507"><day>01</day><month>05</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright &#169; 2023 Mu&#241;oz, Caparr&#243;s, Albillos and Franc&#233;s</copyright-statement><copyright-year>2023</copyright-year><copyright-holder>Mu&#241;oz, Caparr&#243;s, Albillos and Franc&#233;s</copyright-holder><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="fimmu-14-1139554.pdf"/><abstract><p>Cirrhosis is the common end-stage of chronic liver diseases of different etiology. The altered bile acids metabolism in the cirrhotic liver and the increase in the blood-brain barrier permeability, along with the progressive dysbiosis of intestinal microbiota, contribute to gut immunity changes, from compromised antimicrobial host defense to pro-inflammatory adaptive responses. In turn, these changes elicit a disruption in the epithelial and gut vascular barriers, promoting the increased access of potential pathogenic microbial antigens to portal circulation, further aggravating liver disease. After summarizing the key aspects of gut immunity during homeostasis, this review is intended to update the contribution of liver and brain metabolites in shaping the intestinal immune status and, in turn, to understand how the loss of homeostasis in the gut-associated lymphoid tissue, as present in cirrhosis, cooperates in the advanced chronic liver disease progression. Finally, several therapeutic approaches targeting the intestinal homeostasis in cirrhosis are discussed.</p></abstract><kwd-group><kwd>cirrhosis</kwd><kwd>gut permeability</kwd><kwd>inflammation</kwd><kwd>bacterial translocation</kwd><kwd>microbiota</kwd></kwd-group><funding-group><award-group><funding-source id="cn001"><institution-wrap><institution>Instituto de Salud Carlos III
</institution><institution-id institution-id-type="doi">10.13039/501100004587</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn001">PI20/01302, PMP21/0082</award-id></award-group><award-group><funding-source id="cn002"><institution-wrap><institution>Ministerio de Ciencia e Innovaci&#243;n
</institution><institution-id institution-id-type="doi">10.13039/501100004837</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn002">PID2019-107036RB-I00</award-id></award-group><award-group><funding-source id="cn003"><institution-wrap><institution>Conselleria de Cultura, Educaci&#243;n y Ciencia, Generalitat Valenciana
</institution><institution-id institution-id-type="doi">10.13039/501100014849</institution-id></institution-wrap></funding-source><award-id award-type="contract" rid="cn003">Prometeo 2021/033</award-id></award-group></funding-group><funding-group><funding-statement>This work was supported by grants from the Ministerio de Ciencia e Innovaci&#243;n, Instituto de Salud Carlos III PI20/01302 awarded to AA, and Ministerio de Ciencia e Innovaci&#243;n, Instituto de Salud Carlos III PID2019-107036RB-I00 and PMP21/0082, and Generalitat Valenciana Prometeo 2021/033 awarded to RF. CIBEREHD is funded by the Instituto de Salud Carlos III using grants cofinanced by the European Development Regional Fund &#8220;A way to achieve Europe&#8221; (EDRF).</funding-statement></funding-group><counts><fig-count count="1"/><table-count count="1"/><equation-count count="0"/><ref-count count="147"/><page-count count="12"/><word-count count="5795"/></counts><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1"><label>1</label><title>Background</title><p>Cirrhosis is an evolving liver disease that leads to portal hypertension and hepatic insufficiency. During cirrhosis, the composition of intestinal microbiota is dynamically altered. This microbiota state, known as dysbiosis, induces an increased intestinal permeability and gut barrier dysfunction. In these conditions, the homeostatic contribution of the liver and the brain to gut immunity that is established through the gut-liver-brain axis is then affected, accelerating disease decompensation and complications (<xref rid="B1" ref-type="bibr">1</xref>, <xref rid="B2" ref-type="bibr">2</xref>). This review outlines intestinal immunity characteristics in the homeostatic condition and how metabolites derived from liver and brain during cirrhosis contribute to disturbing the gut tissue microenvironment, which further contributes to progression of advanced chronic disease.</p><sec id="s1_1"><label>1.1</label><title>Intestinal immune milieu in homeostasis</title><p>Multiple barriers separate the commensal microbes in the gut from blood, avoiding bacteria entering the systemic circulation. From the lumen inwards, tissue arrangement comprises the mucus layer, the epithelial barrier, the immune system layer, and the gut vascular barrier (GVB) (<xref rid="B3" ref-type="bibr">3</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><fig position="float" id="f1" orientation="portrait"><label>Figure&#160;1</label><caption><p>Gut-liver-brain axis in health and cirrhosis, highlighting the intestinal immune milieu. The intestinal epithelial barrier is a multi-layered structure that separates bacteria in the intestinal lumen from the systemic circulation. In healthy individuals, eubiosis, a tolerant immune system and an efficient innate antibacterial defense maintain the integrity of the epithelial and vascular barriers. Cirrhosis is associated with an altered microbiome which results from decreased bile flow, with deficient levels of primary but increased of secondary bile acids, together with intestinal hypomotility. Gut dysbiosis drives bacterial colonization of the inner mucous layer of the intestine, which facilitates the interaction of bacteria with the immune system, resulting in intestinal inflammation with recruitment and activation of immune system cells. Composition and severity of intestinal inflammation change with cirrhosis progression. Intestinal inflammation in the compensated stage is featured by activated innate cells, including DCs producing TNF-&#945; and showing increased phagocytic and migratory abilities, along with the activation of the adaptive immune system, mainly located in the intraepithelial compartment. In the decompensated stage, intestinal immune system derangement is characterized by non-activated DCs, with lowered TNF-&#945; secretion, and deficient phagocytosis and migration abilities, as well as expansion of activated macrophages and Th1 lymphocytes with concomitant Th17 reduction. Inflammation results in the release of proinflammatory cytokines and ROS, which worsens epithelial and the vascular barrier damage, hyperpermeability and access of bacterial products to the liver (via portal vein Flow) and to the systemic circulation. Elevated systemic levels of proinflammatory cytokines, PAMPs and DAMPs accelerate cirrhosis progression and increase the blood-brain-barrier permeability, inducing neuroinflammation (astrocyte swelling, activated microglia and immune system infiltration), which activates hypothalamic-pituitary-adrenal axis, and affects intestinal barrier integrity. Within the gut, the altered microbiota can produce neurotransmitters, amino acids and microbial metabolites. These metabolites can travel through portal circulation to interact with the host immune system, influence metabolism and/or affect local neuronal cells of the enteric nervous system and afferent pathways of the vagus nerve that signal directly to the brain. DC, dendritic cell; Treg, regulatory T cells; Tc, cytotoxic T cell; Th, helper T cell; ILC, innate lymphoid cell; NK cell, natural killer cell; NKT cell, natural killer T cell, MAIT cell, mucosal-associated invariant T cell, AMP, antimicrobial peptides; MUC-2, mucin-2; FXR, Farnesoid X receptor, TJ, Tight junction, BA, bile acid; NO, nitric oxide; IL-, interleukin; CCL2, C-C motif ligand 2; PAMPs, pathogen-associated molecular patterns; 318 DAMPs, damage-associated molecular patterns, ROS, radical oxygen species; TNF-&#947;, tumor necrosis factor-alpha; IFN-&#947;, interferon &#947;; ACTH, adrenocorticotrophic hormone; BBB, blood-brain barrier; HPA, hypothalamic-pituitary-adrenal.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="fimmu-14-1139554-g001.jpg"/></fig><p>The mucus layer acts as a frontline barrier separating the intestinal lumen from underlying tissues. Mucins comprising the outer thick mucus layer, which help the adhesion of microorganisms and their products, are produced by goblet and epithelial cells, and facilitate the opsonizing activity of plasma cell-derived secretory Immunoglobulin A (sIgA) (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>). Mucins can be found either as membrane-attached, such as MUC1, MUC3, MUC4, MUC13, and MUC17, or as secreted gel-forming mucins, like MUC2, MUC5AC, MUC5B, and MUC6 (<xref rid="B47" ref-type="bibr">47</xref>). Particularly, MUC2 offers static protection and restricts the potential activation of dendritic cells (DC), conferring them a tolerogenic state through stimulation of interleukin 10 (IL-10) production and TNF-&#945; signaling inhibition (<xref rid="B48" ref-type="bibr">48</xref>).</p><table-wrap position="float" id="T1" orientation="portrait"><label>Table&#160;1</label><caption><p>Role of immune cells involved in gut homeostasis and abnormalities produced in cirrhosis.</p></caption><table frame="hsides" rules="groups"><thead><tr><th valign="top" colspan="2" align="left" rowspan="1">Cell type</th><th valign="top" align="left" rowspan="1" colspan="1">Immune function</th><th valign="top" align="left" rowspan="1" colspan="1">References</th><th valign="top" align="left" rowspan="1" colspan="1">Intestinal mucosa abnormalities in cirrhosis</th><th valign="top" align="left" rowspan="1" colspan="1">References</th></tr></thead><tbody><tr><td valign="middle" rowspan="5" align="left" colspan="1">
<bold>Intestinal epithelial cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Enterocytes</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Form TJ structures; produce antimicrobial molecules (Reg3&#947; and Lypd8); express pIgR</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B4" ref-type="bibr">4</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Shedding and apoptosis, decreased TJs and AMPs Reg3&#946; and Reg3&#947;</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>&#8211;<xref rid="B7" ref-type="bibr">7</xref>)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Paneth cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Produce AMPs &#945;-defensin 5 (HD5), HD6 and Reg3&#947;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B8" ref-type="bibr">8</xref>, <xref rid="B9" ref-type="bibr">9</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Defective production of AMPs (&#945;-defensins and Reg3 proteins)</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B7" ref-type="bibr">7</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Goblet cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Produce mucin and anti-inflammatory molecules (trefoil factor 3, RELMbeta)</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B12" ref-type="bibr">12</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Loss of goblet cells and decreased MUC2 resulting in reduced mucous layer thickness</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B13" ref-type="bibr">13</xref>)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Microfold (M) cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Uptake of antigens</td><td valign="top" rowspan="2" align="left" colspan="1">(<xref rid="B4" ref-type="bibr">4</xref>, <xref rid="B14" ref-type="bibr">14</xref>)</td><td valign="middle" rowspan="2" align="left" colspan="1"/><td valign="top" rowspan="2" align="center" colspan="1">
<italic toggle="yes">
<sup>N/R</sup>
</italic>
</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Tuft cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Sense luminal helminths</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>sIgA (produced by plasma cells)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Binding and retention of bacteria in the<break/>intestinal lumen</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B15" ref-type="bibr">15</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Reduced synthesis in the jejunum and diminished fecal content</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>)</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>Neutrophils</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Elimination of translocated microbes, facilitation of mucosal healing, recruitment of other immune cells</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B18" ref-type="bibr">18</xref>, <xref rid="B19" ref-type="bibr">19</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<sup>N/R</sup>
</italic>
</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>Macrophages</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Bactericidal activity, transfer of acquired antigen to DC for presentation to T cells, production of immunoregulatory cytokines IL-10 and TGF-&#946;</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B20" ref-type="bibr">20</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Activated CD14+Trem1+iNOS+ secreting IL-6, IL-8, NO and MCP-1</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B21" ref-type="bibr">21</xref>)</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>Dendritic cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Maintenance of tolerogenic state; initiation and differentiation of adaptive immune responses</td><td valign="top" align="left" rowspan="1" colspan="1">(<xref rid="B22" ref-type="bibr">22</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Deficient phagocytosis, migration capacity, and TNF-&#945; production</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B23" ref-type="bibr">23</xref>)</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>Eosinophils</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Cytotoxic effect, modulation of B and T cells</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B24" ref-type="bibr">24</xref>, <xref rid="B25" ref-type="bibr">25</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<sup>N/R</sup>
</italic>
</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>Mast cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Innate response, antigen clearance, release of histamine, proteases, and prostaglandins</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B27" ref-type="bibr">27</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<sup>N/R</sup>
</italic>
</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>ILC1 (including NK cells)</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Cytotoxicity, macrophage activation</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>, <xref rid="B29" ref-type="bibr">29</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Expanded showing increased IFN-&#947; production</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>ILC2</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Immunity to helminths</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<sup>N/R</sup>
</italic>
</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>ILC3</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Host defense against extracellular bacteria and fungi</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Reduced IL-22 production by ILC3s which promotes diminished intestinal Reg3&#947; expression, resulting in bacterial translocation to the liver</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B30" ref-type="bibr">30</xref>)</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>iNKTs</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Response to lipid antigen, production of cytokines and chemokines</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B28" ref-type="bibr">28</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Expanded in intestinal lamina propria, but reduced IL-17 production</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>Tgamma-delta</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Defense against infection and wound healing</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B31" ref-type="bibr">31</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Expanded in intestinal lamina propria</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>MAIT cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Modulation of host-microbial interplay, antibacterial immunity</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B32" ref-type="bibr">32</xref>, <xref rid="B33" ref-type="bibr">33</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<sup>N/R</sup>
</italic>
</td></tr><tr><td valign="middle" rowspan="4" align="left" colspan="1">
<bold>Th CD4+</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Th17</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Neutrophilic inflammation, response to extracellular bacteria and fungi</td><td valign="middle" rowspan="2" align="left" colspan="1">(<xref rid="B34" ref-type="bibr">34</xref>&#8211;<xref rid="B39" ref-type="bibr">39</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Diminished in the lamina propria</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Th1</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Monocytic inflammation, response to intracellular bacteria, protozoans, and viruses</td><td valign="middle" align="left" rowspan="1" colspan="1">Increased production of IFN-&#947; in the small intestine</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Th22</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Mucosal host defense, secretion of beta-defensins</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B40" ref-type="bibr">40</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1"/><td valign="top" align="center" rowspan="1" colspan="1">
<italic toggle="yes">
<sup>N/R</sup>
</italic>
</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Treg</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Tissue homeostasis and tolerogenic cytokine production</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B41" ref-type="bibr">41</xref>&#8211;<xref rid="B44" ref-type="bibr">44</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Expanded in the lamina propria</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td></tr><tr><td valign="middle" colspan="2" align="left" rowspan="1">
<bold>Tc CD8+</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Cytotoxic activity</td><td valign="middle" align="left" rowspan="1" colspan="1">(<xref rid="B45" ref-type="bibr">45</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Expanded showing high IFN-&#947; production</td><td valign="top" align="center" rowspan="1" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td></tr><tr><td valign="middle" rowspan="2" align="left" colspan="1">
<bold>Memory T cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Central memory T cells</bold>
</td><td valign="middle" align="left" rowspan="1" colspan="1">Re-exposure with their cognate antigen recirculating between secondary lymph organs and blood</td><td valign="top" rowspan="2" align="left" colspan="1">(<xref rid="B46" ref-type="bibr">46</xref>)</td><td valign="middle" align="left" rowspan="1" colspan="1">Expanded in the small intestine</td><td valign="top" rowspan="2" align="center" colspan="1">(<xref rid="B5" ref-type="bibr">5</xref>)</td></tr><tr><td valign="middle" align="left" rowspan="1" colspan="1">
<bold>Effector memory T cells</bold>
</td><td valign="top" align="left" rowspan="1" colspan="1">Re-exposure with their cognate antigen recirculating between peripheral circulation and tissue</td><td valign="middle" align="left" rowspan="1" colspan="1">Expanded in the small intestine</td></tr></tbody></table><table-wrap-foot><fn><p>N/R, none reported.</p></fn></table-wrap-foot></table-wrap><p>The physical barrier integrated by mucins is reinforced by antimicrobial peptides (AMPs), that are produced by enterocytes and Paneth cells, and by microbial metabolites from commensal microbiota (<xref rid="B49" ref-type="bibr">49</xref>). AMPs act as efficient barrier against enteric pathogens (<xref rid="B50" ref-type="bibr">50</xref>). Cathelicidins, defensins and the regenerating islet-derived protein III-gamma (Reg3&#947;) prompt antimicrobial and anti-inflammatory functions, and induce immune cell recruitment, bacterial phagocytosis, and epithelial healing. The recently described lipopeptides, C14-R1 and C12-R2, have also shown AMP activity through the production of reactive oxygen species (ROS) (<xref rid="B51" ref-type="bibr">51</xref>). On the other hand, the barrier features of the mucus layer are completed with microbial metabolites produced by bacterial fermentation of dietary components, such as short-chain fatty acids (SCFAs). SCFAs regulate most intestinal epithelial cell functions, including cell turnover (<xref rid="B52" ref-type="bibr">52</xref>), mucus secretion by goblet cells (<xref rid="B53" ref-type="bibr">53</xref>), tight junction (TJ) proteins expression (<xref rid="B54" ref-type="bibr">54</xref>) and inflammasome- or hypoxia-inducible factor-mediated epithelial integrity (<xref rid="B55" ref-type="bibr">55</xref>, <xref rid="B56" ref-type="bibr">56</xref>).</p><p>Below the mucus layer, the epithelial barrier maintains gut homeostasis and regulates immune responses (<xref rid="B50" ref-type="bibr">50</xref>). Epithelial cells are sealed by tight and adherens junctions (TJ and AJ, respectively), which are finely regulated by the influence of proinflammatory cytokines, and by signaling kinases and cytoskeleton, like myosin light chain kinases (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B57" ref-type="bibr">57</xref>). Intestinal epithelial cells possess a tightly regulated and specifically localized set of Pathogen-associated molecular pattern (PAMP) receptors and their signaling components for microbial detection. This innate immune-recognition equipment enables them to respond to microorganisms, thereby initiating the first steps in the host-pathogen interaction by regulating the immune response (<xref rid="B58" ref-type="bibr">58</xref>, <xref rid="B59" ref-type="bibr">59</xref>). In addition, some studies unveil intestinal epithelial cells as non-professional antigen-presenting cells inducing inflammation or promoting tolerance (<xref rid="B60" ref-type="bibr">60</xref>&#8211;<xref rid="B62" ref-type="bibr">62</xref>). Following the detection of intestinal microbes through PAMP receptors, some specialized epithelial cells, such as goblet or Paneth cells (<xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>), respond generating molecules that protect mucosa from commensal microbes and invading pathogenic microorganisms, as mentioned above.</p><p>The Gut-associated lymphoid tissue (GALT) comprises both organized tissues such as lymphoid follicles, Peyer&#8217;s patches, and mesenteric lymph nodes (MLNs), where immune responses are induced, and scattered immune cells throughout the surface epithelium of the mucosa and in the underlying lamina propria, where effector functions are carried out (<xref rid="B63" ref-type="bibr">63</xref>).</p><p>In the steady state, neutrophils, located in the lamina propria, produce ROS and neutrophil extracellular traps (NETs) helping eliminating microbes translocated across the mucosal epithelium and facilitating tissue healing or immune cell recruitment (<xref rid="B18" ref-type="bibr">18</xref>). Eosinophils produce mediators including fibroblast growth factor (FGF)-2 and transforming growth factor (TGF)-&#946; to promote tissue remodeling and repair (<xref rid="B64" ref-type="bibr">64</xref>, <xref rid="B65" ref-type="bibr">65</xref>). In addition, mast cells, localizing along the gastrointestinal tract, differentially express PAMP receptors depending on their location and develop a fundamental regulatory and defensive function (<xref rid="B26" ref-type="bibr">26</xref>, <xref rid="B66" ref-type="bibr">66</xref>). Intestinal macrophages remove senescent, apoptotic epithelial cells and promote epithelial integrity. They can also capture and destroy any bacteria that breach the barrier or send cellular processes across the epithelial barrier to sample luminal contents, which transfer to Dendritic cells (DCs) for presentation to T cells in the draining MLNs. Through their production of immunoregulatory cytokines, such as IL-10 and TGF-&#946;, they maintain and facilitate secondary expansion of regulatory T cells (Tregs). In a similar manner, they support T helper (Th)17 cells and type 3 Innate lymphoid cells (ILC3) through their production of IL1-&#946; (<xref rid="B20" ref-type="bibr">20</xref>). Also, differentially localized DC subsets can capture translocated IgA immune complexes (<xref rid="B67" ref-type="bibr">67</xref>) and continuously sample the lumen to establish a tolerogenic response to innocuous antigens (<xref rid="B22" ref-type="bibr">22</xref>). Finally, several innate lymphocytes like NK cells, invariant natural killer T cells (iNKT), and mucosal-associated invariant T (MAIT) cells have been identified as important in controlling gut immunity. Together with ILC3 and gamma delta (&#947;&#948;)T, both iNKT and MAIT cells contribute to gut barrier integrity by producing IL-22, which is also important for promoting antibacterial defense (<xref rid="B68" ref-type="bibr">68</xref>&#8211;<xref rid="B70" ref-type="bibr">70</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref> and <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><p>Th cells control the entry of translocated antigens at the gut (<xref rid="B71" ref-type="bibr">71</xref>). However, the sustained activation and proliferation of the Th response is an impeller of chronic inflammation. On the other hand, regulatory T (Treg) cells in the gut secrete TGF-&#946; that negatively regulates T cell function (<xref rid="B41" ref-type="bibr">41</xref>). Both Th17 and Treg subsets show reciprocal phenotype plasticity based on the environmental milieu (<xref rid="B72" ref-type="bibr">72</xref>). Any imbalance between these populations in a tissue highly exposed to bacteria such as the gut barrier leads to a dysregulated mucosal immune response, with consequences for liver regulation and disease (<xref rid="B73" ref-type="bibr">73</xref>, <xref rid="B74" ref-type="bibr">74</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref> and <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><p>Just below the effector sites of the immune system layer, an additional cellular barrier, the GVB, controls entry into the portal circulation and access to the liver (<xref rid="B75" ref-type="bibr">75</xref>). Thus, if a molecule or a microorganism crosses the muco-epithelial barrier and escapes the local immune system, even to reach the systemic circulation the GVB must be disrupted. The GVB is characterized by the presence of TJ and AJ, which strictly control paracellular trafficking of solutes and fluids, together with other cell types, such as pericytes or fibroblasts, associated with the microvasculature and involved in the maintenance of the GVB, where they form a vascular unit.</p></sec><sec id="s1_2"><label>1.2</label><title>The liver contributes to shaping gut immune landscape</title><p>Liver-derived molecules interact with the gut regional immune system defining tolerogenic or pathological interactions. In addition to metabolic functions, bile acids (BAs) are synthesized in the liver and incorporated by intestinal epithelial cells, exerting several immunomodulatory activities (<xref rid="B76" ref-type="bibr">76</xref>). Firstly, BAs induce anti-inflammatory responses through farnesoid X receptor (FXR) and Takeda G-protein-coupled receptor 5 (TGR5) on many tissues such as liver, intestine, or brain. Particularly, in macrophages, TGR5 activation inhibits nuclear translocation of nuclear factor &#954;B (NF-kB), reducing the secretion of proinflammatory mediators such as TNF-&#945;, IL-1&#946;, IL-6, IFN-&#947; and nitric oxide (NO) (<xref rid="B77" ref-type="bibr">77</xref>, <xref rid="B78" ref-type="bibr">78</xref>). Secondly, BAs interact with intestinal microbiota helping maintain its eubiotic state. In fact, a decrease in BAs levels may induce an overgrowth of pathogenic Gram-negative bacteria, with raised levels of lipopolysaccharide (LPS) (<xref rid="B79" ref-type="bibr">79</xref>) and subsequent induction of proinflammatory responses in the gut. Moreover, BAs such as deoxycholic acid have a direct impact on microbial membranes due to its hydrophobicity and detergent properties. Indirectly, BAs binding to FXR induces the control of gut microbiota through the production of intestinal antimicrobial molecules, such as angiogenin 1, that help control microbial overgrowth (<xref rid="B80" ref-type="bibr">80</xref>).</p><p>Together with BAs, IgA is the main isotype participating in microbial control in the gut-liver axis. Though main contribution on microbiota regulation is proportioned by sIgA produced by intestinal plasma cells, liver-derived IgA also contributes to the regulation of intestinal microbiota (<xref rid="B81" ref-type="bibr">81</xref>). Regardless the source, the sIgA patrols the intestinal mucus barrier, protecting epithelial cells and opsonizing luminal bacteria (<xref rid="B15" ref-type="bibr">15</xref>) without inducing a deleterious local inflammatory response (<xref rid="B82" ref-type="bibr">82</xref>). In fact, sIgA deficiency has been shown to disrupt the gut barrier <italic toggle="yes">via</italic> increased translocation of commensal bacteria (<xref rid="B83" ref-type="bibr">83</xref>).</p><p>The rest of metabolites and intermediaries drained by the liver into systemic circulation such as free fatty acids, choline and ethanol metabolites have also an impact on the physiological conditions of the gut, as they contribute to modulate the gut barrier interaction between the microbiome and the immune system (<xref rid="B73" ref-type="bibr">73</xref>).</p></sec><sec id="s1_3"><label>1.3</label><title>The brain contribution in gut immune response</title><p>Gut-brain axis involves a bidirectional communication route with a cellular and molecular interchange modulated by threatening inflammatory insults. Intestinal microbiota and its products can directly modulate the central nervous system (CNS) immune profile (<xref rid="B84" ref-type="bibr">84</xref>). Though specific immune responses coming from CNS and controlling the gut remains still elusive, different mechanisms have been recently uncovered (<xref rid="B85" ref-type="bibr">85</xref>). On this point, systemic, neuronal, and cellular intercommunication pathways have been described. First, systemic proinflammatory elements can alter blood brain barrier (BBB), as it happens with GVB, leading to increased permeability and passage of inflammatory products along the axis. Thus, neuroinflammatory triggering by such products could give rise to potential intestinal tract immune responses, as glucocorticoids release under hypothalamic-pituitary-function adrenal (HPA) activation, can modulate intestinal functions (<xref rid="B84" ref-type="bibr">84</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). Moreover, neuronal connection of the CNS with the gut allows the signaling communication and the inhibition of proinflammatory macrophages, as well as M cell function to control pathogen irruption and microbiota homeostasis (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>). Additionally, dysbiosis induced by stress and intestinal Th17 production of IL-17A, has been described to feedback this stress response (<xref rid="B86" ref-type="bibr">86</xref>).</p></sec></sec><sec id="s2"><label>2</label><title>Altered gut-liver-brain axis in cirrhosis</title><sec id="s2_1"><label>2.1</label><title>Gut barrier dysfunction in cirrhosis</title><p>In cirrhosis, the intestinal barrier is markedly disturbed, prompting the passage of live bacteria and bacterial components or metabolites to the internal milieu in experimental models and patients (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B87" ref-type="bibr">87</xref>). This derangement increases in severity as cirrhosis progresses (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><p>Gut barrier dysfunction affects both physical (muco-epithelial and GV barriers) and immunological layers, and results in hyperpermeability of the whole intestine (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B88" ref-type="bibr">88</xref>). Disrupted mucosal barrier integrity plays a pivotal pathophysiological role not only because it increases the risk of severe complications such as spontaneous infections, but also and more importantly, because it affects the natural history of liver disease and patient survival.</p><sec id="s2_1_1"><label>2.1.1</label><title>Deranged muco-epithelial and gut vascular barrier permeability</title><p>Intestinal dysbiosis is the dominant player that sets the basis for epithelial barrier disruption. The gut microbiome in cirrhosis is characterized by reduced diversity and shows a significantly increased abundance of potentially pathogenic bacteria such as <italic toggle="yes">Enterococcaceae</italic>, <italic toggle="yes">Staphylococcaceae</italic> and <italic toggle="yes">Enterobacteriaceae</italic>, and a reduced relative abundance of potentially beneficial autochthonous bacteria such as <italic toggle="yes">Lachnospiraceae</italic> and <italic toggle="yes">Ruminococcaceae</italic> (<xref rid="B89" ref-type="bibr">89</xref>&#8211;<xref rid="B91" ref-type="bibr">91</xref>). Dysbiosis likely results from reduced bile flow with deficient levels of primary but increased levels of secondary BAs to the gut (<xref rid="B92" ref-type="bibr">92</xref>&#8211;<xref rid="B94" ref-type="bibr">94</xref>), which in turn results in reduced intestinal FXR signaling (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B95" ref-type="bibr">95</xref>), along with intestinal hypomotility. Intestinal dysbiosis and changes in BAs drive intestinal barrier functional abnormalities through changes in mucosal immunity and deficiencies in innate mechanisms of defense against bacteria (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><p>The microbiome has been proposed to play a key role in mucus synthesis, release and barrier-function (<xref rid="B96" ref-type="bibr">96</xref>). In bile duct ligated (BDL) cirrhotic rats, there is lower mucus thickness, mucus weight per ileum length, and goblet cell numbers in the terminal ileum compared to healthy controls, predominantly with a reduction in mucin-filled goblet cells. This is associated with bacterial overgrowth in the inner most mucus layer (<xref rid="B13" ref-type="bibr">13</xref>). The closer proximity of bacteria to epithelial cells is one of the factors contributing to the passage of bacterial products in cirrhosis.</p><p>In humans and experimental models of cirrhosis, the observed structural changes in the small intestine include increased inter-enterocyte spacing with disorganization of TJ and AJ proteins, decreased intestinal mucosal proliferation and proliferation/apoptosis ratio, increased intestinal oxidative stress, edema of the lamina propria, infiltration by immune system cells, fibromuscular proliferation and a lowered villous/crypt ratio (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B97" ref-type="bibr">97</xref>&#8211;<xref rid="B99" ref-type="bibr">99</xref>). Diminished expression of zonula occludens-1 (ZO-1), occludin, claudin-1 and e-cadherin, and increased expression of claudin-2 have been reported in the small intestine of patients and experimental models of cirrhosis, especially in decompensated ones, with a concomitant increase produced in intestinal permeability, supporting the dynamic relationship between portal hypertension, gut bacterial translocation (GBT) and TJ and AJ expression in intestinal epithelial cells (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B98" ref-type="bibr">98</xref>). Portal hypertension results in intestinal mucosa hypoperfusion and hypoxia, which exacerbate oxidative damage in the gut mucosa (<xref rid="B100" ref-type="bibr">100</xref>). ROS can also enhance bacterial adhesion to epithelial cells and facilitate GBT across the mucosa (<xref rid="B101" ref-type="bibr">101</xref>). Increased cyclooxygenase-2 activity contributes to intestinal barrier disruption, as its inhibition increases ZO-1 and e-cadherin expression as well as intestinal permeability in rats with cirrhosis (<xref rid="B102" ref-type="bibr">102</xref>).</p><p>GVB is also profoundly altered in pre-clinical models of cirrhosis (<xref rid="B13" ref-type="bibr">13</xref>). This pathological endothelial permeability and accessibility in cirrhotic mice is associated with augmented expression of plasmalemma vesicle-associated protein (PV1), an integral membrane protein associated to the diaphragms of endothelial fenestrae, in intestinal vessels. Gut dysbiosis drives GVB disruption associated with liver disease, as mice receiving fecal microbiota transplantation (FMT) from high fat diet-fed mice, a pre-clinical model of non-alcoholic steatohepatitis, displayed increased PV1 expression in the small intestine compared to recipients receiving FMT from mice under control diet (<xref rid="B103" ref-type="bibr">103</xref>).</p></sec><sec id="s2_1_2"><label>2.1.2</label><title>Compromised antimicrobial host defense</title><p>Besides damage to the physical barriers, cirrhosis is also associated with compromised antimicrobial host defense, which concerns certain specialized populations of epithelial cells having particularly important roles in innate immune defense of the intestine, such as Paneth cells, as well as innate immune cells. In this sense, the loss of Paneth cell &#945;-5, &#945;-6 and &#945;-7-defensins, lysozyme and Reg3&#947; AMPs has been described in experimental models and patients with cirrhosis (<xref rid="B6" ref-type="bibr">6</xref>, <xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B30" ref-type="bibr">30</xref>, <xref rid="B104" ref-type="bibr">104</xref>). Interestingly, some of these changes have been associated with GBT in CCl<sub>4</sub>-induced ascitic cirrhotic rats. Moreover, a diminished activity against <italic toggle="yes">E. coli</italic> and <italic toggle="yes">Enterococcus faecalis</italic> in the distal ileum has been found in rats with cirrhosis with GBT compared with non-GBT (<xref rid="B11" ref-type="bibr">11</xref>). Of note, a negative correlation between &#945;-5, and &#945;-7-defensins expression and circulating endotoxin levels has been described in cirrhotic patients (<xref rid="B104" ref-type="bibr">104</xref>). Therefore, a deficiency in Paneth cell AMPs likely decreases mucosal killing activity with a consequent shift of the luminal bacterial composition associated with intestinal bacterial overgrowth and increased GBT in liver cirrhosis. In this regard, angiogenin-1 is an AMP transcriptionally regulated by FXR (<xref rid="B105" ref-type="bibr">105</xref>), which displays a selective bactericidal activity against Gram negative bacteria and modulates intestinal inflammation (<xref rid="B106" ref-type="bibr">106</xref>). Reduced ileum expression of angiogenin-1 has been observed in rats with CCl<sub>4</sub>-induced cirrhosis with ascites suffering GBT (<xref rid="B10" ref-type="bibr">10</xref>).</p></sec><sec id="s2_1_3"><label>2.1.3</label><title>Skewed gut innate and adaptive immune responses</title><p>Both structural changes and compromised antimicrobial host defense in the small intestine allow for bacterial colonization of the inner mucous layer and further promote the interaction of an altered gut microbiota, including an augmented bacterial burden and abundance of potentially pathogenetic taxa, with mucosal immune system cells. The consequence of this interaction between pathobionts and GALT is a state of subclinical inflammation with activation of innate immune cells, leading to proinflammatory cytokine and chemokine release, oxidative stress, and further recruitment of lymphocytes (<xref rid="B11" ref-type="bibr">11</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B21" ref-type="bibr">21</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B108" ref-type="bibr">108</xref>).</p><p>Experimental studies have shown the increased expression of Toll-like receptor 4 (TLR4) and the proinflammatory cytokine TNF-&#945; in the terminal ileum of CCl<sub>4</sub>-cirrhotic rats, especially in those with GBT (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B109" ref-type="bibr">109</xref>). In addition, the TNF-&#945; levels in both the serum and multiple organs are significantly increased in CCl<sub>4</sub>-cirrhotic rats with compared with those without GBT (<xref rid="B109" ref-type="bibr">109</xref>) Similarly, patients with advanced cirrhosis with ascites exhibit elevated blood TNF-&#945; levels along with an increase in the local production of TNF-&#945; in the MLNs, which correlates with GBT (<xref rid="B110" ref-type="bibr">110</xref>). These findings suggest that, in cirrhosis, bacterial overgrowth and endotoxins significantly stimulate the secretion of TNF-&#945; in the small intestine through the activation of TLR4. In the gut, immune dysregulation with a functional proinflammatory switch contributes to perpetuate intestinal barrier failure and GBT, both to the MLNs, and to the liver through the portal-venous route, due to disruption of the GVB (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B109" ref-type="bibr">109</xref>). Subsequently, clearance deficiency by the cirrhotic liver allows bacteria and PAMPs getting into the systemic circulation (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B13" ref-type="bibr">13</xref>, <xref rid="B23" ref-type="bibr">23</xref>, <xref rid="B107" ref-type="bibr">107</xref>&#8211;<xref rid="B109" ref-type="bibr">109</xref>, <xref rid="B111" ref-type="bibr">111</xref>). Recirculation of gut activated effector immune system cells along with inflammatory mediators, such as TNF-&#945;, PAMPs and damage-associated molecular patterns (DAMPs) spreads the systemic inflammatory response inducing circulatory and remote organ dysfunction (<xref rid="B91" ref-type="bibr">91</xref>, <xref rid="B107" ref-type="bibr">107</xref>, <xref rid="B109" ref-type="bibr">109</xref>&#8211;<xref rid="B113" ref-type="bibr">113</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><p>Regarding to innate immune cells, a deranged innate immune response has an important contribution to the gut barrier disruption that occurs in cirrhosis patients and experimental models and includes: i) activated CD14+Trem1+inducible nitric oxide synthase (iNOS)+ macrophages, secreting IL-8, CCL2, IL-6 and NO, which correlate with an increased expression of claudin-2 (<xref rid="B21" ref-type="bibr">21</xref>); ii) an increased number of activated CD103+ DCs producing TNF-&#945; and showing higher phagocytic and migratory abilities, when GBT is not present, which switch to a non-activated phenotype, and relatively deficient function when cirrhosis progresses and GBT occurs, likely facilitating bacterial passage (<xref rid="B23" ref-type="bibr">23</xref>); iii) the expansion of IFN-&#947;-secreting &#947;&#948;T- and NK cells, that could be related with TJ disorganization (<xref rid="B5" ref-type="bibr">5</xref>); and iv) a reduced IL-22 production by ILC3s which promotes diminished intestinal Reg3&#947; expression, resulting in GBT to the liver (<xref rid="B30" ref-type="bibr">30</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref> and <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><p>Changes in the small intestine&#8217;s adaptive immune response are also prominent especially as cirrhosis progresses to the ascites stage, and consist of: i) high infiltration of several activated Th and cytotoxic T (Tc) CD8&#945;&#946;+ cell subsets (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B109" ref-type="bibr">109</xref>); ii) high proportion of Th1 and IFN-&#947;-producing Tc cells, which directly correlates with gut permeability that is probably due to endocytosis of TJ proteins (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B114" ref-type="bibr">114</xref>); iii) Th17 depletion, which also contributes to barrier damage as IL-17 play a role in intestinal epithelium homeostasis by inducing TJ function and AMPs production (<xref rid="B115" ref-type="bibr">115</xref>); iv) increased numbers of Tregs in a likely response to bacterial challenge, although they seem unable to offset the proinflammatory immune response; and v) an increased number of B cells, which contrasts with the reduced synthesis of IgA in the jejunum of rats with cirrhosis and the diminished fecal IgA content of the intestine in cirrhotic rats (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B16" ref-type="bibr">16</xref>, <xref rid="B17" ref-type="bibr">17</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref> and <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><p>Intestinal dysbiosis leads to a dysregulation of the innate and adaptive immune responses of the intestinal mucosa that further contribute to bacterial mucosal adhesion and colonization, as well as intestinal hyperpermeability. As cirrhosis progresses from the preascitic to the ascitic stage a dysregulated mucosal immune system contributes to the derangement of epithelial TJ, reduced secretion of AMPs and impaired phagocytic function of DCs, which facilitate the increased passage of bacteria and bacterial products to the systemic circulation (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref> and <xref rid="T1" ref-type="table">
<bold>Table&#160;1</bold>
</xref>).</p><p>The key pathogenetic role of bacteria is confirmed by the reversibility of most intestinal immune abnormalities and increased gut permeability provoked by antibiotic-induced microbiome reorganization (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B23" ref-type="bibr">23</xref>). Consistently, antibiotics reduce immune cell infiltration in the intestinal mucosa of cirrhotic animals. Of note, bowel decontamination normalizes the frequencies of proinflammatory IFN-&#947; and TNF-&#945; cytokines, the phagocytic activity of DCs, and gut permeability, as revealed by a reduction in fecal albumin loss and by fully suppressed GBT in cirrhotic rats with ascites (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B23" ref-type="bibr">23</xref>).</p></sec></sec><sec id="s2_2"><label>2.2</label><title>Disturbed gut-brain function during cirrhosis</title><p>A mild neurocognitive dysfunction is present in as much as 80% of patients with cirrhosis. This condition, named minimal or covert hepatic encephalopathy (HE) affects quality of life (<xref rid="B116" ref-type="bibr">116</xref>) and predicts the development of overt HE (<xref rid="B117" ref-type="bibr">117</xref>). This complication encompasses a wide range of cognitive, psychomotor and psychiatric disturbances that heralds a poor prognosis with negative impact on health-related quality of life, liver transplant priority and patient survival (<xref rid="B118" ref-type="bibr">118</xref>, <xref rid="B119" ref-type="bibr">119</xref>).</p><p>From a neurologic point of view, hepatic encephalopathy in cirrhosis is primarily astroglial in nature, characterized by Alzheimer type 2 astrocytosis together with activation of microglia indicative of neuroinflammation (<xref rid="B120" ref-type="bibr">120</xref>, <xref rid="B121" ref-type="bibr">121</xref>). Inflammation and hyperammonemia are associated with enhanced cognitive impairment in patients with cirrhosis (<xref rid="B122" ref-type="bibr">122</xref>). It has been proposed that inflammation synergistically acts with ammonia in driving nitrosation of brain proteins in BDL cirrhotic rats (<xref rid="B123" ref-type="bibr">123</xref>). Proinflammatory cytokine levels are also increased in patients with covert hepatic encephalopathy (<xref rid="B124" ref-type="bibr">124</xref>), and these inflammatory mediators have been correlated with serum ammonia in patients with extrahepatic portal venous obstruction (<xref rid="B125" ref-type="bibr">125</xref>). The relevance of the neutrophil response in the pathogenesis of hepatic encephalopathy has also been documented (<xref rid="B126" ref-type="bibr">126</xref>), and proinflammatory IL-1&#946; and IL-6 have been correlated with neurocognitive scores and with health-related quality of live questionnaires in patients with cirrhosis (<xref rid="B127" ref-type="bibr">127</xref>) (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p><p>A link between altered flora (higher <italic toggle="yes">Veillonellaceae</italic>), poor cognition, endotoxemia, and inflammation (IL-6, TNF-&#945;, IL-2, and IL-13) has been described in cirrhotic patients with compared with those without HE. In addition, in the cirrhosis group, <italic toggle="yes">Alcaligeneceae</italic> and <italic toggle="yes">Porphyromonadaceae</italic> positively correlated with cognitive impairment (<xref rid="B128" ref-type="bibr">128</xref>). An increased risk of cognitive impairment in patients with cirrhosis and bacterial infections has been reported, including those with subclinical cognitive alterations (<xref rid="B129" ref-type="bibr">129</xref>). In this latter group of patients, even bacterial antigen translocation, without the need of an over infection, is associated with increased serum ammonia and NOx levels, and a more severe neurocognitive condition (<xref rid="B130" ref-type="bibr">130</xref>).</p><p>Finally, the relationship between Th17 cells and cognitive impairment has also been documented. Th17 cells have been described to cross the BBB and promote brain injury in neurological diseases (<xref rid="B131" ref-type="bibr">131</xref>). Systemic inflammation associated with cirrhosis may therefore increase BBB permeability and facilitate brain T cell recruitment in the context of advanced liver disease (<xref rid="f1" ref-type="fig">
<bold>Figure&#160;1</bold>
</xref>).</p></sec></sec><sec id="s3"><label>3</label><title>Therapeutic approaches targeting the intestinal homeostasis in cirrhosis</title><p>Abnormalities in microbiota composition and bacterial overgrowth set the stage for the gut-liver axis disruption with intestinal barrier failure, which is distinctive of cirrhosis. These facts enable increased passage to the bloodstream of bacteria or their products, which promote systemic inflammation and bacterial infections, and worsen cirrhosis progression. The disrupted gut-liver axis observed in cirrhosis is a topic of active research, considering its contribution to disease progression. We thereby briefly summarize novel therapeutic approaches to target the gut-liver axis aimed to halt cirrhosis progression.</p><sec id="s3_1"><label>3.1</label><title>Antibiotics</title><p>The effects of bowel decontamination with poorly absorbable antibiotics are the redistribution of microbiota composition, reduced intestinal permeability and GBT, and improved proinflammatory activation of mucosal and circulating immune cells along with circulatory dysfunction in human and experimental models (<xref rid="B5" ref-type="bibr">5</xref>, <xref rid="B112" ref-type="bibr">112</xref>). Norfloxacin and ciprofloxacin are standard of care for primary and secondary prevention of spontaneous bacterial peritonitis, and norfloxacin reduces the risk of infection and 6-month mortality in patients with advanced cirrhosis (<xref rid="B132" ref-type="bibr">132</xref>, <xref rid="B133" ref-type="bibr">133</xref>). Rifaximin is a broad-spectrum compound that improves and prevents overt hepatic encephalopathy and ameliorates systemic inflammation and endotoxinemia in patients with cirrhosis and encephalopathy (<xref rid="B134" ref-type="bibr">134</xref>, <xref rid="B135" ref-type="bibr">135</xref>). Rather than promoting bowel decontamination, rifaximin exerts its effects by eliminating polarization of the gut microbiome <italic toggle="yes">via</italic> suppression of mucin-degrading species rich in sialidase and known to induce gut barrier damage while preserving beta-diversity, e.g. <italic toggle="yes">Streptococcus</italic> and <italic toggle="yes">Veillonella spp</italic> (<xref rid="B135" ref-type="bibr">135</xref>). Rifaximin associated with simvastatin to prevent Acute-on-Chronic Liver Failure and reduce complications in decompensated cirrhosis is being currently tested in clinical trials (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03780673">NCT03780673</ext-link>). Alternatives to antibiotics are a topic of research as their long-term use has been linked to reduced bacterial diversity and multidrug-resistant microorganisms (<xref rid="B136" ref-type="bibr">136</xref>).</p></sec><sec id="s3_2"><label>3.2</label><title>Probiotics and diet</title><p>Probiotics displace resident dysbiotic bacteria and reconstitute a healthy microbiome. <italic toggle="yes">Bifidobacterium pseudocatenulatum</italic> CECT7765 induces a shift towards an TLR2-mediated anti-inflammatory cytokine profile in intestinal lymphocytes and macrophages, improves gut barrier integrity, reduces intestinal permeability, and decreases bacterial DNA translocation, serum endotoxin levels and burden of bacterial antigens in the liver in cirrhotic patients and experimental models (<xref rid="B137" ref-type="bibr">137</xref>&#8211;<xref rid="B139" ref-type="bibr">139</xref>). <italic toggle="yes">Lactobacillus rhamnosus GG</italic> supernatant therapy also increases mRNA expression of TJ proteins and reduces intestinal permeability in a mouse model of chronic-binge alcohol feeding. This therapy led to a decrease of GBT to the liver and an overall balance restored of Tregs, Th17s, and IL-17 (<xref rid="B140" ref-type="bibr">140</xref>, <xref rid="B141" ref-type="bibr">141</xref>). Furthermore, probiotic supplementation has shown significantly increase serum neopterin levels and the production of ROS by neutrophils (<xref rid="B142" ref-type="bibr">142</xref>). These findings might explain the beneficial effects of probiotics on immune function, as well as in ameliorating gut barrier dysfunction in cirrhosis. However, studies on the impact of probiotics on cirrhosis complications and progression, including hepatic encephalopathy, have severe methodological limitations and patient numbers have been too small to draw valid conclusions. In parallel, an international study has shown that a diet rich in coffee, tea, fresh vegetables and fermented milk is associated with an increased diversity of microbiota species and reduced number of hospitalizations in patients with cirrhosis, suggesting the benefits of dietary modulation of the gut microbiome in favor of liver health (<xref rid="B143" ref-type="bibr">143</xref>).</p></sec><sec id="s3_3"><label>3.3</label><title>Gut molecular adsorbents</title><p>Another therapeutic approach is to reduce the amount of bacterial toxin being absorbed from the intestine in patients and experimental models with chronic liver disease. In contrast to the strategies based on the prolonged use of antibiotics that reduce intestinal bacterial populations, use of scavengers of bacterial toxins has the advantage of avoiding the risk of establishing antimicrobial drug resistant intestinal bacteria. Yaq-001 is a non-absorbable activated charcoal with a high adsorptive capacity for endotoxins and other products of bacterial metabolism preventing their absorption into the bloodstream. Evidence in BDL rats showed that Yaq-001 was associated with shifts in microbiome composition, attenuated the LPS-induced production of ROS by monocytes, and reductions in liver injury and portal pressure (<xref rid="B144" ref-type="bibr">144</xref>). A phase-II clinical study in patients with cirrhosis and diuretic-sensitive ascites treated with Yaq-001 or placebo for 12 weeks suggested proof of a mechanism that Yak-001 modulated systemic endotoxinemia and inflammation by improving gut inflammation and its permeability (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT03202498">NCT03202498</ext-link>).</p></sec><sec id="s3_4"><label>3.4</label><title>FMT</title><p>FMT restores a healthy gut microbial environment and physiological colonization <italic toggle="yes">via</italic> different routes of administration. Microbiota transplantation in patients with recurrent hepatic encephalopathy proved safe in the long-term and has shown to rescue antibiotic-associated disruption in microbial diversity, improve cognitive function, and reduce encephalopathy recurrence and hospitalizations (<xref rid="B145" ref-type="bibr">145</xref>). These studies have involved a limited number of patients and efficacy trials are pending. In this regard, FMT is currently being tested in a randomized controlled trial in patients with decompensated cirrhosis to address survival and liver related outcomes (<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:clinical-trial" xlink:href="NCT04932577">NCT04932577</ext-link>).</p></sec><sec id="s3_5"><label>3.5</label><title>FXR agonists</title><p>Diminished luminal BA availability in cirrhosis provokes a reduction in intestinal FXR signaling which seems, at least partly, to mediate the gut barrier disruption in cirrhosis, as FXR-agonists reduce GBT <italic toggle="yes">via</italic> the portal-venous route to the liver (<xref rid="B13" ref-type="bibr">13</xref>). In experimental cirrhosis, FXR activation by obeticholic acid (OCA) increases ileal protein expression of the main TJ proteins and AMP secretion (<xref rid="B10" ref-type="bibr">10</xref>, <xref rid="B13" ref-type="bibr">13</xref>), influences intestinal epithelial cell proliferation and apoptosis (<xref rid="B146" ref-type="bibr">146</xref>), and exerts potent antiinflammatory actions in the intestine, stabilizing epithelial integrity (<xref rid="B10" ref-type="bibr">10</xref>). Herein, OCA impacts the mucous machinery by increasing ileal goblet cell numbers in cirrhotic animals (<xref rid="B13" ref-type="bibr">13</xref>). On the vascular side, the FXR agonist OCA stabilizes the dysfunctional GVB in experimental cirrhosis (<xref rid="B13" ref-type="bibr">13</xref>).</p></sec><sec id="s3_6"><label>3.6</label><title>Administration of IL-22</title><p>IL-22, a cytokine member in IL-10 family, is mainly secreted by various immune cells, such as ILCs and MAIT cells, which targets epithelial cells in several organs, including the intestine and the liver. IL-22 promotes survival and proliferation of hepatocytes and liver progenitor cells, thereby promoting liver repair (<xref rid="B147" ref-type="bibr">147</xref>). Additionally, IL-22 increases the expression of intestinal Reg3 lectins, which maintain low bacterial colonization of the inner mucus layer and reduce GBT to the liver. In a mouse model of ethanol-induced liver disease, intestinal IL-22 has the beneficial effect of reducing GBT in the intestine by increasing the expression of Reg3&#947;. Bacteria engineered to produce IL-22 in the intestine (without increasing systemic IL-22) ameliorate experimental ethanol-induced steatohepatitis <italic toggle="yes">via</italic> induction of Reg3&#947; (<xref rid="B30" ref-type="bibr">30</xref>). Importantly, due to this combination of protective effects in the liver and in the intestinal barrier IL-22 is a promising drug for the treatment of alcoholic hepatitis.</p></sec></sec><sec id="s4"><label>4</label><title>Concluding remarks</title><p>While the gut immunity during homeostasis plays a crucial role in liver and brain functions, mainly through its interaction with symbiotic microbiota, the progression of advanced chronic liver disease significantly compromises the immunological behavior at the gut and brain barriers of cirrhotic patients. Therefore, therapeutic options aimed at restoring gut immune homeostasis in these patients are of relevance to prevent cirrhosis-derived complications. However, despite intense experimental research, its translation into clinic remains a lengthy goal.</p></sec><sec sec-type="author-contributions" id="s5"><title>Author contributions</title><p>LM, EC, AA, RF: manuscript design, writing and final version approval.</p></sec></body><back><sec sec-type="COI-statement" id="s7"><title>Conflict of interest</title><p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p></sec><sec sec-type="disclaimer" id="s8"><title>Publisher&#8217;s note</title><p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p></sec><ref-list><title>References</title><ref id="B1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brescia</surname><given-names>P</given-names></name><name name-style="western"><surname>Rescigno</surname><given-names>M</given-names></name></person-group>. <article-title>The gut vascular barrier: a new player in the gut-liver-brain axis</article-title>. <source>Trends Mol Med</source> (<year>2021</year>) <volume>27</volume>:<page-range>844&#8211;55</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.molmed.2021.06.007</pub-id><pub-id pub-id-type="pmid">34229973</pub-id></mixed-citation></ref><ref id="B2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gin&#232;s</surname><given-names>P</given-names></name><name name-style="western"><surname>Krag</surname><given-names>A</given-names></name><name name-style="western"><surname>Abraldes</surname><given-names>JG</given-names></name><name name-style="western"><surname>Sol&#224;</surname><given-names>E</given-names></name><name name-style="western"><surname>Fabrellas</surname><given-names>N</given-names></name><name name-style="western"><surname>Kamath</surname><given-names>PS</given-names></name></person-group>. <article-title>Liver cirrhosis</article-title>. <source>Lancet</source> (<year>2021</year>) <volume>398</volume>:<page-range>1359&#8211;76</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(21)01374-X</pub-id><pub-id pub-id-type="pmid">34543610</pub-id></mixed-citation></ref><ref id="B3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okumura</surname><given-names>R</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K</given-names></name></person-group>. <article-title>Maintenance of intestinal homeostasis by mucosal barriers</article-title>. <source>Inflammation Regener</source> (<year>2018</year>) <volume>38</volume>:<fpage>5</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s41232-018-0063-z</pub-id><pub-id pub-id-type="pmcid">PMC5879757</pub-id><pub-id pub-id-type="pmid">29619131</pub-id></mixed-citation></ref><ref id="B4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Goto</surname><given-names>Y</given-names></name></person-group>. <article-title>Epithelial cells as a transmitter of signals from commensal bacteria and host immune cells</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>2057</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2019.02057</pub-id><pub-id pub-id-type="pmid">31555282</pub-id><pub-id pub-id-type="pmcid">PMC6724641</pub-id></mixed-citation></ref><ref id="B5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mu&#241;oz</surname><given-names>L</given-names></name><name name-style="western"><surname>Borrero</surname><given-names>MJ</given-names></name><name name-style="western"><surname>&#218;beda</surname><given-names>M</given-names></name><name name-style="western"><surname>Conde</surname><given-names>E</given-names></name><name name-style="western"><surname>Del Campo</surname><given-names>R</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Serrano</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Intestinal immune dysregulation driven by dysbiosis promotes barrier disruption and bacterial translocation in rats with cirrhosis</article-title>. <source>Hepatology</source> (<year>2019</year>) <volume>70</volume>(<issue>3</issue>):<page-range>925&#8211;38</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.30349</pub-id><pub-id pub-id-type="pmid">30414342</pub-id></mixed-citation></ref><ref id="B6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yan</surname><given-names>AW</given-names></name><name name-style="western"><surname>Fouts</surname><given-names>DE</given-names></name><name name-style="western"><surname>Brandl</surname><given-names>J</given-names></name><name name-style="western"><surname>St&#228;rkel</surname><given-names>P</given-names></name><name name-style="western"><surname>Torralba</surname><given-names>M</given-names></name><name name-style="western"><surname>Schott</surname><given-names>E</given-names></name><etal/></person-group>. <article-title>Enteric dysbiosis associated with a mouse model of alcoholic liver disease</article-title>. <source>Hepatology</source> (<year>2011</year>) <volume>53</volume>:<fpage>96</fpage>&#8211;<lpage>105</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.24018</pub-id><pub-id pub-id-type="pmid">21254165</pub-id><pub-id pub-id-type="pmcid">PMC3059122</pub-id></mixed-citation></ref><ref id="B7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schnabl</surname><given-names>B</given-names></name></person-group>. <article-title>Linking intestinal homeostasis and liver disease</article-title>. <source>Curr Opin Gastroenterol</source> (<year>2013</year>) <volume>29</volume>:<page-range>264&#8211;70</page-range>. doi: <pub-id pub-id-type="doi">10.1097/MOG.0b013e32835ff948</pub-id><pub-id pub-id-type="pmcid">PMC4077188</pub-id><pub-id pub-id-type="pmid">23493073</pub-id></mixed-citation></ref><ref id="B8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ouellette</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Bevins</surname><given-names>CL</given-names></name></person-group>. <article-title>Paneth cell defensins and innate immunity of the small bowel</article-title>. <source>Inflammation Bowel Dis</source> (<year>2001</year>) <volume>7</volume>:<fpage>43</fpage>&#8211;<lpage>50</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00054725-200102000-00007</pub-id><pub-id pub-id-type="pmid">11233660</pub-id></mixed-citation></ref><ref id="B9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Clevers</surname><given-names>HC</given-names></name><name name-style="western"><surname>Bevins</surname><given-names>CL</given-names></name></person-group>. <article-title>Paneth cells: maestros of the small intestinal crypts</article-title>. <source>Annu Rev Physiol</source> (<year>2013</year>) <volume>75</volume>:<fpage>289</fpage>&#8211;<lpage>311</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-physiol-030212-183744</pub-id><pub-id pub-id-type="pmid">23398152</pub-id></mixed-citation></ref><ref id="B10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ubeda</surname><given-names>M</given-names></name><name name-style="western"><surname>Lario</surname><given-names>M</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>L</given-names></name><name name-style="western"><surname>Borrero</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Serrano</surname><given-names>M</given-names></name><name name-style="western"><surname>S&#225;nchez-D&#237;az</surname><given-names>AM</given-names></name><etal/></person-group>. <article-title>Obeticholic acid reduces bacterial translocation and inhibits intestinal inflammation in cirrhotic rats</article-title>. <source>J Hepatol</source> (<year>2016</year>) <volume>64</volume>:<page-range>1049&#8211;57</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2015.12.010</pub-id><pub-id pub-id-type="pmid">26723896</pub-id></mixed-citation></ref><ref id="B11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Teltschik</surname><given-names>Z</given-names></name><name name-style="western"><surname>Wiest</surname><given-names>R</given-names></name><name name-style="western"><surname>Beisner</surname><given-names>J</given-names></name><name name-style="western"><surname>Nuding</surname><given-names>S</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Schoelmerich</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Intestinal bacterial translocation in rats with cirrhosis is related to compromised Paneth cell antimicrobial host defense</article-title>. <source>Hepatology</source> (<year>2012</year>) <volume>55</volume>(<issue>4</issue>):<page-range>1154&#8211;63</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.24789</pub-id><pub-id pub-id-type="pmid">22095436</pub-id></mixed-citation></ref><ref id="B12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kim</surname><given-names>YS</given-names></name><name name-style="western"><surname>Ho</surname><given-names>SB</given-names></name></person-group>. <article-title>Intestinal goblet cells and mucins in health and disease: recent insights and progress</article-title>. <source>Curr Gastroenterol Rep</source> (<year>2010</year>) <volume>12</volume>:<page-range>319&#8211;30</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11894-010-0131-2</pub-id><pub-id pub-id-type="pmcid">PMC2933006</pub-id><pub-id pub-id-type="pmid">20703838</pub-id></mixed-citation></ref><ref id="B13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorribas</surname><given-names>M</given-names></name><name name-style="western"><surname>Jakob</surname><given-names>MO</given-names></name><name name-style="western"><surname>Yilmaz</surname><given-names>B</given-names></name><name name-style="western"><surname>Li</surname><given-names>H</given-names></name><name name-style="western"><surname>Stutz</surname><given-names>D</given-names></name><name name-style="western"><surname>Noser</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>FXR modulates the gut-vascular barrier by regulating the entry sites for bacterial translocation in experimental cirrhosis</article-title>. <source>J Hepatol</source> (<year>2019</year>) <volume>71</volume>:<page-range>1126&#8211;40</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2019.06.017</pub-id><pub-id pub-id-type="pmid">31295531</pub-id></mixed-citation></ref><ref id="B14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schneider</surname><given-names>C</given-names></name><name name-style="western"><surname>O'Leary</surname><given-names>CE</given-names></name><name name-style="western"><surname>Locksley</surname><given-names>RM</given-names></name></person-group>. <article-title>Regulation of immune responses by tuft cells</article-title>. <source>Nat Rev Immunol</source> (<year>2019</year>) <volume>19</volume>:<page-range>584&#8211;93</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41577-019-0176-x</pub-id><pub-id pub-id-type="pmcid">PMC8331098</pub-id><pub-id pub-id-type="pmid">31114038</pub-id></mixed-citation></ref><ref id="B15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macpherson</surname><given-names>AJ</given-names></name><name name-style="western"><surname>McCoy</surname><given-names>KD</given-names></name><name name-style="western"><surname>Johansen</surname><given-names>FE</given-names></name><name name-style="western"><surname>Brandtzaeg</surname><given-names>P</given-names></name></person-group>. <article-title>The immune geography of IgA induction and function</article-title>. <source>Mucosal Immunol</source> (<year>2008</year>) <volume>1</volume>:<fpage>11</fpage>&#8211;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1038/mi.2007.6</pub-id><pub-id pub-id-type="pmid">19079156</pub-id></mixed-citation></ref><ref id="B16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wiest</surname><given-names>R</given-names></name><name name-style="western"><surname>Lawson</surname><given-names>M</given-names></name><name name-style="western"><surname>Geuking</surname><given-names>M</given-names></name></person-group>. <article-title>Pathological bacterial translocation in liver cirrhosis</article-title>. <source>J Hepatol</source> (<year>2014</year>) <volume>60</volume>:<fpage>197</fpage>&#8211;<lpage>209</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2013.07.044</pub-id><pub-id pub-id-type="pmid">23993913</pub-id></mixed-citation></ref><ref id="B17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Pelletier</surname><given-names>G</given-names></name><name name-style="western"><surname>Briantais</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Buffet</surname><given-names>C</given-names></name><name name-style="western"><surname>Pillot</surname><given-names>J</given-names></name><name name-style="western"><surname>Etienne</surname><given-names>JP</given-names></name></person-group>. <article-title>Serum and intestinal secretory IgA in alcoholic cirrhosis of the liver</article-title>. <source>Gut</source> (<year>1982</year>) <volume>23</volume>:<page-range>475&#8211;80</page-range>. doi: <pub-id pub-id-type="doi">10.1136/gut.23.6.475</pub-id><pub-id pub-id-type="pmcid">PMC1419709</pub-id><pub-id pub-id-type="pmid">7076021</pub-id></mixed-citation></ref><ref id="B18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fournier</surname><given-names>BM</given-names></name><name name-style="western"><surname>Parkos</surname><given-names>CA</given-names></name></person-group>. <article-title>The role of neutrophils during intestinal inflammation</article-title>. <source>Mucosal Immunol</source> (<year>2012</year>) <volume>5</volume>:<page-range>354&#8211;66</page-range>. doi: <pub-id pub-id-type="doi">10.1038/mi.2012.24</pub-id><pub-id pub-id-type="pmid">22491176</pub-id></mixed-citation></ref><ref id="B19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Brinkmann</surname><given-names>V</given-names></name><name name-style="western"><surname>Zychlinsky</surname><given-names>A</given-names></name></person-group>. <article-title>Beneficial suicide: why neutrophils die to make NETs</article-title>. <source>Nat Rev Microbiol</source> (<year>2007</year>) <volume>5</volume>:<page-range>577&#8211;82</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nrmicro1710</pub-id><pub-id pub-id-type="pmid">17632569</pub-id></mixed-citation></ref><ref id="B20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bain</surname><given-names>CC</given-names></name><name name-style="western"><surname>Schridde</surname><given-names>A</given-names></name></person-group>. <article-title>Origin, differentiation, and function of intestinal macrophages</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>2733</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.02733</pub-id><pub-id pub-id-type="pmid">30538701</pub-id><pub-id pub-id-type="pmcid">PMC6277706</pub-id></mixed-citation></ref><ref id="B21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du Plessis</surname><given-names>J</given-names></name><name name-style="western"><surname>Vanheel</surname><given-names>H</given-names></name><name name-style="western"><surname>Janssen</surname><given-names>CE</given-names></name><name name-style="western"><surname>Roos</surname><given-names>L</given-names></name><name name-style="western"><surname>Slavik</surname><given-names>T</given-names></name><name name-style="western"><surname>Stivaktas</surname><given-names>PI</given-names></name><etal/></person-group>. <article-title>Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function</article-title>. <source>J Hepatol</source> (<year>2013</year>) <volume>58</volume>:<page-range>1125&#8211;32</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2013.01.038</pub-id><pub-id pub-id-type="pmid">23402745</pub-id></mixed-citation></ref><ref id="B22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Stagg</surname><given-names>AJ</given-names></name></person-group>. <article-title>Intestinal dendritic cells in health and gut inflammation</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>2883</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.02883</pub-id><pub-id pub-id-type="pmid">30574151</pub-id><pub-id pub-id-type="pmcid">PMC6291504</pub-id></mixed-citation></ref><ref id="B23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munoz</surname><given-names>L</given-names></name><name name-style="western"><surname>Jose Borrero</surname><given-names>M</given-names></name><name name-style="western"><surname>Ubeda</surname><given-names>M</given-names></name><name name-style="western"><surname>Lario</surname><given-names>M</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>D</given-names></name><name name-style="western"><surname>Franc&#233;s</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Interaction between intestinal dendritic cells and bacteria translocated from the gut in rats with cirrhosis</article-title>. <source>Hepatology</source> (<year>2012</year>) <volume>56</volume>:<page-range>1861&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.25854</pub-id><pub-id pub-id-type="pmid">22611024</pub-id></mixed-citation></ref><ref id="B24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Rosenberg</surname><given-names>HF</given-names></name><name name-style="western"><surname>Dyer</surname><given-names>KD</given-names></name><name name-style="western"><surname>Foster</surname><given-names>PS</given-names></name></person-group>. <article-title>Eosinophils: changing perspectives in health and disease</article-title>. <source>Nat Rev Immunol</source> (<year>2013</year>) <volume>13</volume>:<fpage>9</fpage>&#8211;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nri3341</pub-id><pub-id pub-id-type="pmid">23154224</pub-id><pub-id pub-id-type="pmcid">PMC4357492</pub-id></mixed-citation></ref><ref id="B25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yantiss</surname><given-names>RK</given-names></name></person-group>. <article-title>Eosinophils in the GI tract: how many is too many and what do they mean</article-title>? <source>Mod Pathol</source> (<year>2015</year>) <volume>28 Suppl 1</volume>:<fpage>S7</fpage>&#8211;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1038/modpathol.2014.132</pub-id><pub-id pub-id-type="pmid">25560601</pub-id></mixed-citation></ref><ref id="B26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albert-Bayo</surname><given-names>M</given-names></name><name name-style="western"><surname>Paracuellos</surname><given-names>I</given-names></name><name name-style="western"><surname>Gonzalez-Castro</surname><given-names>AM</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Urrutia</surname><given-names>A</given-names></name><name name-style="western"><surname>Rodr&#237;guez-Lagunas</surname><given-names>MJ</given-names></name><name name-style="western"><surname>Alonso-Cotoner</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Intestinal mucosal mast cells: Key modulators of barrier function and homeostasis</article-title>. <source>Cells</source> (<year>2019</year>) <volume>8</volume>(<issue>2</issue>):<fpage>135</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.3390/cells8020135</pub-id><pub-id pub-id-type="pmid">30744042</pub-id><pub-id pub-id-type="pmcid">PMC6407111</pub-id></mixed-citation></ref><ref id="B27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Frossi</surname><given-names>B</given-names></name><name name-style="western"><surname>Mion</surname><given-names>F</given-names></name><name name-style="western"><surname>Sibilano</surname><given-names>R</given-names></name><name name-style="western"><surname>Danelli</surname><given-names>L</given-names></name><name name-style="western"><surname>Pucillo</surname><given-names>CEM</given-names></name></person-group>. <article-title>Is it time for a new classification of mast cells? what do we know about mast cell heterogeneity</article-title>? <source>Immunol Rev</source> (<year>2018</year>) <volume>282</volume>:<fpage>35</fpage>&#8211;<lpage>46</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1111/imr.12636</pub-id><pub-id pub-id-type="pmid">29431204</pub-id></mixed-citation></ref><ref id="B28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Eberl</surname><given-names>G</given-names></name><name name-style="western"><surname>Colonna</surname><given-names>M</given-names></name><name name-style="western"><surname>Di Santo</surname><given-names>JP</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>AN</given-names></name></person-group>. <article-title>Innate lymphoid cells. innate lymphoid cells: a new paradigm in immunology</article-title>. <source>Science</source> (<year>2015</year>) <volume>348</volume>:<fpage>aaa6566</fpage>. doi:&#160;<pub-id pub-id-type="doi">10.1126/science.aaa6566</pub-id><pub-id pub-id-type="pmid">25999512</pub-id><pub-id pub-id-type="pmcid">PMC5658207</pub-id></mixed-citation></ref><ref id="B29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Poggi</surname><given-names>A</given-names></name><name name-style="western"><surname>Benelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Vene</surname><given-names>R</given-names></name><name name-style="western"><surname>Costa</surname><given-names>D</given-names></name><name name-style="western"><surname>Ferrari</surname><given-names>N</given-names></name><name name-style="western"><surname>Tosetti</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Human gut-associated natural killer cells in health and disease</article-title>. <source>Front Immunol</source> (<year>2019</year>) <volume>10</volume>:<elocation-id>961</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fimmu.2019.00961</pub-id><pub-id pub-id-type="pmid">31130953</pub-id><pub-id pub-id-type="pmcid">PMC6509241</pub-id></mixed-citation></ref><ref id="B30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Hendrikx</surname><given-names>T</given-names></name><name name-style="western"><surname>Duan</surname><given-names>Y</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Oh</surname><given-names>JH</given-names></name><name name-style="western"><surname>Alexander</surname><given-names>LM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name><etal/></person-group>. <article-title>Bacteria engineered to produce IL-22 in intestine induce expression of REG3G to reduce ethanol-induced liver disease in mice</article-title>. <source>Gut</source> (<year>2019</year>) <volume>68</volume>:<page-range>1504&#8211;15</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1136/gutjnl-2018-317232</pub-id><pub-id pub-id-type="pmcid">PMC6387784</pub-id><pub-id pub-id-type="pmid">30448775</pub-id></mixed-citation></ref><ref id="B31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Nielsen</surname><given-names>MM</given-names></name><name name-style="western"><surname>Witherden</surname><given-names>DA</given-names></name><name name-style="western"><surname>Havran</surname><given-names>WL</given-names></name></person-group>. <article-title>Gammadelta T cells in homeostasis and host defence of epithelial barrier tissues</article-title>. <source>Nat Rev Immunol</source> (<year>2017</year>) <volume>17</volume>:<page-range>733&#8211;45</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nri.2017.101</pub-id><pub-id pub-id-type="pmcid">PMC5771804</pub-id><pub-id pub-id-type="pmid">28920588</pub-id></mixed-citation></ref><ref id="B32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mortier</surname><given-names>C</given-names></name><name name-style="western"><surname>Govindarajan</surname><given-names>S</given-names></name><name name-style="western"><surname>Venken</surname><given-names>K</given-names></name><name name-style="western"><surname>Elewaut</surname><given-names>D</given-names></name></person-group>. <article-title>It takes "Guts" to cause joint inflammation: Role of innate-like T cells</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>1489</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.01489</pub-id><pub-id pub-id-type="pmid">30008717</pub-id><pub-id pub-id-type="pmcid">PMC6033969</pub-id></mixed-citation></ref><ref id="B33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Treiner</surname><given-names>E</given-names></name><name name-style="western"><surname>Duban</surname><given-names>L</given-names></name><name name-style="western"><surname>Bahram</surname><given-names>S</given-names></name><name name-style="western"><surname>Radosavljevic</surname><given-names>M</given-names></name><name name-style="western"><surname>Wanner</surname><given-names>V</given-names></name><name name-style="western"><surname>Tilloy</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Selection of evolutionarily conserved mucosal-associated invariant T cells by MR1</article-title>. <source>Nature</source> (<year>2003</year>) <volume>422</volume>:<page-range>164&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature01433</pub-id><pub-id pub-id-type="pmid">12634786</pub-id></mixed-citation></ref><ref id="B34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Weaver</surname><given-names>CT</given-names></name><name name-style="western"><surname>Elson</surname><given-names>CO</given-names></name><name name-style="western"><surname>Fouser</surname><given-names>LA</given-names></name><name name-style="western"><surname>Kolls</surname><given-names>JK</given-names></name></person-group>. <article-title>The Th17 pathway and inflammatory diseases of the intestines, lungs, and skin</article-title>. <source>Annu Rev Pathol</source> (<year>2013</year>) <volume>8</volume>:<fpage>477</fpage>&#8211;<lpage>512</lpage>. doi: <pub-id pub-id-type="doi">10.1146/annurev-pathol-011110-130318</pub-id><pub-id pub-id-type="pmid">23157335</pub-id><pub-id pub-id-type="pmcid">PMC3965671</pub-id></mixed-citation></ref><ref id="B35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Murphy</surname><given-names>KM</given-names></name><name name-style="western"><surname>Stockinger</surname><given-names>B</given-names></name></person-group>. <article-title>Effector T cell plasticity: flexibility in the face of changing circumstances</article-title>. <source>Nat Immunol</source> (<year>2010</year>) <volume>11</volume>:<page-range>674&#8211;80</page-range>. doi: <pub-id pub-id-type="doi">10.1038/ni.1899</pub-id><pub-id pub-id-type="pmcid">PMC3249647</pub-id><pub-id pub-id-type="pmid">20644573</pub-id></mixed-citation></ref><ref id="B36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shaw</surname><given-names>MH</given-names></name><name name-style="western"><surname>Kamada</surname><given-names>N</given-names></name><name name-style="western"><surname>Kim</surname><given-names>YG</given-names></name><name name-style="western"><surname>N&#250;&#241;ez</surname><given-names>G</given-names></name></person-group>. <article-title>Microbiota-induced IL-1beta, but not IL-6, is critical for the development of steady-state TH17 cells in the intestine</article-title>. <source>J Exp Med</source> (<year>2012</year>) <volume>209</volume>:<page-range>251&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1084/jem.20111703</pub-id><pub-id pub-id-type="pmcid">PMC3280878</pub-id><pub-id pub-id-type="pmid">22291094</pub-id></mixed-citation></ref><ref id="B37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>II</given-names></name><name name-style="western"><surname>McKenzie</surname><given-names>BS</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Tadokoro</surname><given-names>CE</given-names></name><name name-style="western"><surname>Lepelley</surname><given-names>A</given-names></name><name name-style="western"><surname>Lafaille</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>The orphan nuclear receptor RORgammat directs the differentiation program of proinflammatory IL-17+ T helper cells</article-title>. <source>Cell</source> (<year>2006</year>) <volume>126</volume>:<page-range>1121&#8211;33</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2006.07.035</pub-id><pub-id pub-id-type="pmid">16990136</pub-id></mixed-citation></ref><ref id="B38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ivanov</surname><given-names>II</given-names></name><name name-style="western"><surname>Frutos Rde</surname><given-names>L</given-names></name><name name-style="western"><surname>Manel</surname><given-names>N</given-names></name><name name-style="western"><surname>Yoshinaga</surname><given-names>K</given-names></name><name name-style="western"><surname>Rifkin</surname><given-names>DB</given-names></name><name name-style="western"><surname>Sartor</surname><given-names>RB</given-names></name><etal/></person-group>. <article-title>Specific microbiota direct the differentiation of IL-17-producing T-helper cells in the mucosa of the small intestine</article-title>. <source>Cell Host Microbe</source> (<year>2008</year>) <volume>4</volume>:<page-range>337&#8211;49</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2008.09.009</pub-id><pub-id pub-id-type="pmcid">PMC2597589</pub-id><pub-id pub-id-type="pmid">18854238</pub-id></mixed-citation></ref><ref id="B39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Atarashi</surname><given-names>K</given-names></name><name name-style="western"><surname>Nishimura</surname><given-names>J</given-names></name><name name-style="western"><surname>Shima</surname><given-names>T</given-names></name><name name-style="western"><surname>Umesaki</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yamamoto</surname><given-names>M</given-names></name><name name-style="western"><surname>Onoue</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>ATP drives lamina propria T(H)17 cell differentiation</article-title>. <source>Nature</source> (<year>2008</year>) <volume>455</volume>:<page-range>808&#8211;12</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature07240</pub-id><pub-id pub-id-type="pmid">18716618</pub-id></mixed-citation></ref><ref id="B40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhang</surname><given-names>N</given-names></name><name name-style="western"><surname>Pan</surname><given-names>HF</given-names></name><name name-style="western"><surname>Ye</surname><given-names>DQ</given-names></name></person-group>. <article-title>Th22 in inflammatory and autoimmune disease: prospects for therapeutic intervention</article-title>. <source>Mol Cell Biochem</source> (<year>2011</year>) <volume>353</volume>:<page-range>41&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s11010-011-0772-y</pub-id><pub-id pub-id-type="pmid">21384158</pub-id></mixed-citation></ref><ref id="B41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>O'Garra</surname><given-names>A</given-names></name><name name-style="western"><surname>Vieira</surname><given-names>P</given-names></name></person-group>. <article-title>Regulatory T cells and mechanisms of immune system control</article-title>. <source>Nat Med</source> (<year>2004</year>) <volume>10</volume>:<page-range>801&#8211;5</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nm0804-801</pub-id><pub-id pub-id-type="pmid">15286781</pub-id></mixed-citation></ref><ref id="B42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Neumann</surname><given-names>C</given-names></name><name name-style="western"><surname>Blume</surname><given-names>J</given-names></name><name name-style="western"><surname>Roy</surname><given-names>U</given-names></name><name name-style="western"><surname>Teh</surname><given-names>PP</given-names></name><name name-style="western"><surname>Vasanthakumar</surname><given-names>A</given-names></name><name name-style="western"><surname>Beller</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>C-maf-dependent treg cell control of intestinal TH17 cells and IgA establishes host-microbiota homeostasis</article-title>. <source>Nat Immunol</source> (<year>2019</year>) <volume>20</volume>:<page-range>471&#8211;81</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-019-0316-2</pub-id><pub-id pub-id-type="pmid">30778241</pub-id></mixed-citation></ref><ref id="B43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ueno</surname><given-names>A</given-names></name><name name-style="western"><surname>Jeffery</surname><given-names>L</given-names></name><name name-style="western"><surname>Kobayashi</surname><given-names>T</given-names></name><name name-style="western"><surname>Hibi</surname><given-names>T</given-names></name><name name-style="western"><surname>Ghosh</surname><given-names>S</given-names></name><name name-style="western"><surname>Jijon</surname><given-names>H</given-names></name></person-group>. <article-title>Th17 plasticity and its relevance to inflammatory bowel disease</article-title>. <source>J Autoimmun</source> (<year>2018</year>) <volume>87</volume>:<fpage>38</fpage>&#8211;<lpage>49</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.jaut.2017.12.004</pub-id><pub-id pub-id-type="pmid">29290521</pub-id></mixed-citation></ref><ref id="B44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sorini</surname><given-names>C</given-names></name><name name-style="western"><surname>Cardoso</surname><given-names>RF</given-names></name><name name-style="western"><surname>Gagliani</surname><given-names>N</given-names></name><name name-style="western"><surname>Villablanca</surname><given-names>EJ</given-names></name></person-group>. <article-title>Commensal bacteria-specific CD4(+) T cell responses in health and disease</article-title>. <source>Front Immunol</source> (<year>2018</year>) <volume>9</volume>:<elocation-id>2667</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2018.02667</pub-id><pub-id pub-id-type="pmid">30524431</pub-id><pub-id pub-id-type="pmcid">PMC6256970</pub-id></mixed-citation></ref><ref id="B45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Luu</surname><given-names>M</given-names></name><name name-style="western"><surname>Weigand</surname><given-names>K</given-names></name><name name-style="western"><surname>Wedi</surname><given-names>F</given-names></name><name name-style="western"><surname>Breidenbend</surname><given-names>C</given-names></name><name name-style="western"><surname>Leister</surname><given-names>H</given-names></name><name name-style="western"><surname>Pautz</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Regulation of the effector function of CD8(+) T cells by gut microbiota-derived metabolite butyrate</article-title>. <source>Sci Rep</source> (<year>2018</year>) <volume>8</volume>:<fpage>14430</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-018-32860-x</pub-id><pub-id pub-id-type="pmid">30258117</pub-id><pub-id pub-id-type="pmcid">PMC6158259</pub-id></mixed-citation></ref><ref id="B46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zundler</surname><given-names>S</given-names></name><name name-style="western"><surname>Becker</surname><given-names>E</given-names></name><name name-style="western"><surname>Schulze</surname><given-names>LL</given-names></name><name name-style="western"><surname>Neurath</surname><given-names>MF</given-names></name></person-group>. <article-title>Immune cell trafficking and retention in inflammatory bowel disease: mechanistic insights and therapeutic advances</article-title>. <source>Gut</source> (<year>2019</year>) <volume>68</volume>:<page-range>1688&#8211;700</page-range>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2018-317977</pub-id><pub-id pub-id-type="pmid">31127023</pub-id></mixed-citation></ref><ref id="B47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tailford</surname><given-names>LE</given-names></name><name name-style="western"><surname>Crost</surname><given-names>EH</given-names></name><name name-style="western"><surname>Kavanaugh</surname><given-names>D</given-names></name><name name-style="western"><surname>Juge</surname><given-names>N</given-names></name></person-group>. <article-title>Mucin glycan foraging in the human gut microbiome</article-title>. <source>Front Genet</source> (<year>2015</year>) <volume>6</volume>:<elocation-id>81</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fgene.2015.00081</pub-id><pub-id pub-id-type="pmid">25852737</pub-id><pub-id pub-id-type="pmcid">PMC4365749</pub-id></mixed-citation></ref><ref id="B48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shan</surname><given-names>M</given-names></name><name name-style="western"><surname>Gentile</surname><given-names>M</given-names></name><name name-style="western"><surname>Yeiser</surname><given-names>JR</given-names></name><name name-style="western"><surname>Walland</surname><given-names>AC</given-names></name><name name-style="western"><surname>Bornstein</surname><given-names>VU</given-names></name><name name-style="western"><surname>Chen</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Mucus enhances gut homeostasis and oral tolerance by delivering immunoregulatory signals</article-title>. <source>Science</source> (<year>2013</year>) <volume>342</volume>:<page-range>447&#8211;53</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.1237910</pub-id><pub-id pub-id-type="pmcid">PMC4005805</pub-id><pub-id pub-id-type="pmid">24072822</pub-id></mixed-citation></ref><ref id="B49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lievin-Le Moal</surname><given-names>V</given-names></name><name name-style="western"><surname>Servin</surname><given-names>AL</given-names></name></person-group>. <article-title>The front line of enteric host defense against unwelcome intrusion of harmful microorganisms: mucins, antimicrobial peptides, and microbiota</article-title>. <source>Clin Microbiol Rev</source> (<year>2006</year>) <volume>19</volume>:<page-range>315&#8211;37</page-range>. doi: <pub-id pub-id-type="doi">10.1128/CMR.19.2.315-337.2006</pub-id><pub-id pub-id-type="pmcid">PMC1471992</pub-id><pub-id pub-id-type="pmid">16614252</pub-id></mixed-citation></ref><ref id="B50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Okumura</surname><given-names>R</given-names></name><name name-style="western"><surname>Takeda</surname><given-names>K</given-names></name></person-group>. <article-title>Roles of intestinal epithelial cells in the maintenance of gut homeostasis</article-title>. <source>Exp Mol Med</source> (<year>2017</year>) <volume>49</volume>:<elocation-id>e338</elocation-id>. doi: <pub-id pub-id-type="doi">10.1038/emm.2017.20</pub-id><pub-id pub-id-type="pmid">28546564</pub-id><pub-id pub-id-type="pmcid">PMC5454438</pub-id></mixed-citation></ref><ref id="B51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zhong</surname><given-names>C</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>F</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>N</given-names></name><name name-style="western"><surname>Zhu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yao</surname><given-names>J</given-names></name><name name-style="western"><surname>Gou</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Ultra-short lipopeptides against gram-positive bacteria while alleviating antimicrobial resistance</article-title>. <source>Eur J Med Chem</source> (<year>2021</year>) <volume>212</volume>:<fpage>113138</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejmech.2020.113138</pub-id><pub-id pub-id-type="pmid">33422980</pub-id></mixed-citation></ref><ref id="B52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Park</surname><given-names>JH</given-names></name><name name-style="western"><surname>Kotani</surname><given-names>T</given-names></name><name name-style="western"><surname>Konno</surname><given-names>T</given-names></name><name name-style="western"><surname>Setiawan</surname><given-names>J</given-names></name><name name-style="western"><surname>Kitamura</surname><given-names>Y</given-names></name><name name-style="western"><surname>Imada</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Promotion of intestinal epithelial cell turnover by commensal bacteria: Role of short-chain fatty acids</article-title>. <source>PloS One</source> (<year>2016</year>) <volume>11</volume>:<elocation-id>e0156334</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0156334</pub-id><pub-id pub-id-type="pmid">27232601</pub-id><pub-id pub-id-type="pmcid">PMC4883796</pub-id></mixed-citation></ref><ref id="B53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Burger-van Paassen</surname><given-names>N</given-names></name><name name-style="western"><surname>Vincent</surname><given-names>A</given-names></name><name name-style="western"><surname>Puiman</surname><given-names>PJ</given-names></name><name name-style="western"><surname>van der Sluis</surname><given-names>M</given-names></name><name name-style="western"><surname>Bouma</surname><given-names>J</given-names></name><name name-style="western"><surname>Boehm</surname><given-names>G</given-names></name><etal/></person-group>. <article-title>The regulation of intestinal mucin MUC2 expression by short-chain fatty acids: implications for epithelial protection</article-title>. <source>Biochem J</source> (<year>2009</year>) <volume>420</volume>:<page-range>211&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1042/BJ20082222</pub-id><pub-id pub-id-type="pmid">19228118</pub-id></mixed-citation></ref><ref id="B54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Kelly</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Battista</surname><given-names>KD</given-names></name><name name-style="western"><surname>Schaefer</surname><given-names>R</given-names></name><name name-style="western"><surname>Lanis</surname><given-names>JM</given-names></name><name name-style="western"><surname>Alexeev</surname><given-names>EE</given-names></name><etal/></person-group>. <article-title>Microbial-derived butyrate promotes epithelial barrier function through IL-10 receptor-dependent repression of claudin-2</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>199</volume>:<page-range>2976&#8211;84</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1700105</pub-id><pub-id pub-id-type="pmcid">PMC5636678</pub-id><pub-id pub-id-type="pmid">28893958</pub-id></mixed-citation></ref><ref id="B55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macia</surname><given-names>L</given-names></name><name name-style="western"><surname>Tan</surname><given-names>J</given-names></name><name name-style="western"><surname>Vieira</surname><given-names>AT</given-names></name><name name-style="western"><surname>Leach</surname><given-names>K</given-names></name><name name-style="western"><surname>Stanley</surname><given-names>D</given-names></name><name name-style="western"><surname>Luong</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Metabolite-sensing receptors GPR43 and GPR109A facilitate dietary fibre-induced gut homeostasis through regulation of the inflammasome</article-title>. <source>Nat Commun</source> (<year>2015</year>) <volume>6</volume>:<fpage>6734</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms7734</pub-id><pub-id pub-id-type="pmid">25828455</pub-id></mixed-citation></ref><ref id="B56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kelly</surname><given-names>CJ</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>L</given-names></name><name name-style="western"><surname>Campbell</surname><given-names>EL</given-names></name><name name-style="western"><surname>Saeedi</surname><given-names>B</given-names></name><name name-style="western"><surname>Scholz</surname><given-names>CC</given-names></name><name name-style="western"><surname>Bayless</surname><given-names>AJ</given-names></name><etal/></person-group>. <article-title>Crosstalk between microbiota-derived short-chain fatty acids and intestinal epithelial HIF augments tissue barrier function</article-title>. <source>Cell Host Microbe</source> (<year>2015</year>) <volume>17</volume>:<page-range>662&#8211;71</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.chom.2015.03.005</pub-id><pub-id pub-id-type="pmcid">PMC4433427</pub-id><pub-id pub-id-type="pmid">25865369</pub-id></mixed-citation></ref><ref id="B57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Du</surname><given-names>L</given-names></name><name name-style="western"><surname>Kim</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Shen</surname><given-names>J</given-names></name><name name-style="western"><surname>Dai</surname><given-names>N</given-names></name></person-group>. <article-title>Crosstalk between inflammation and ROCK/MLCK signaling pathways in gastrointestinal disorders with intestinal hyperpermeability</article-title>. <source>Gastroenterol Res Pract</source> (<year>2016</year>) <volume>2016</volume>:<fpage>7374197</fpage>. doi: <pub-id pub-id-type="doi">10.1155/2016/7374197</pub-id><pub-id pub-id-type="pmid">27746814</pub-id><pub-id pub-id-type="pmcid">PMC5056309</pub-id></mixed-citation></ref><ref id="B58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Price</surname><given-names>AE</given-names></name><name name-style="western"><surname>Shamardani</surname><given-names>K</given-names></name><name name-style="western"><surname>Lugo</surname><given-names>KA</given-names></name><name name-style="western"><surname>Deguine</surname><given-names>J</given-names></name><name name-style="western"><surname>Roberts</surname><given-names>AW</given-names></name><name name-style="western"><surname>Lee</surname><given-names>BL</given-names></name><etal/></person-group>. <article-title>A map of toll-like receptor expression in the intestinal epithelium reveals distinct spatial, cell type-specific, and temporal patterns</article-title>. <source>Immunity</source> (<year>2018</year>) <volume>49</volume>:<fpage>560</fpage>&#8211;<lpage>575 e6</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2018.07.016</pub-id><pub-id pub-id-type="pmid">30170812</pub-id><pub-id pub-id-type="pmcid">PMC6152941</pub-id></mixed-citation></ref><ref id="B59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>McClure</surname><given-names>R</given-names></name><name name-style="western"><surname>Massari</surname><given-names>P</given-names></name></person-group>. <article-title>TLR-dependent human mucosal epithelial cell responses to microbial pathogens</article-title>. <source>Front Immunol</source> (<year>2014</year>) <volume>5</volume>:<elocation-id>386</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fimmu.2014.00386</pub-id><pub-id pub-id-type="pmid">25161655</pub-id><pub-id pub-id-type="pmcid">PMC4129373</pub-id></mixed-citation></ref><ref id="B60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Buning</surname><given-names>J</given-names></name><name name-style="western"><surname>Hundorfean</surname><given-names>G</given-names></name><name name-style="western"><surname>Schmitz</surname><given-names>M</given-names></name><name name-style="western"><surname>Zimmer</surname><given-names>KP</given-names></name><name name-style="western"><surname>Strobel</surname><given-names>S</given-names></name><name name-style="western"><surname>Gebert</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Antigen targeting to MHC class II-enriched late endosomes in colonic epithelial cells: trafficking of luminal antigens studied <italic toggle="yes">in vivo</italic> in crohn's colitis patients</article-title>. <source>FASEB J</source> (<year>2006</year>) <volume>20</volume>:<page-range>359&#8211;61</page-range>. doi: <pub-id pub-id-type="doi">10.1096/fj.05-4807fje</pub-id><pub-id pub-id-type="pmid">16373401</pub-id></mixed-citation></ref><ref id="B61"><label>61</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Dahan</surname><given-names>S</given-names></name><name name-style="western"><surname>Roth-Walter</surname><given-names>F</given-names></name><name name-style="western"><surname>Arnaboldi</surname><given-names>P</given-names></name><name name-style="western"><surname>Agarwal</surname><given-names>S</given-names></name><name name-style="western"><surname>Mayer</surname><given-names>L</given-names></name></person-group>. <article-title>Epithelia: lymphocyte interactions in the gut</article-title>. <source>Immunol Rev</source> (<year>2007</year>) <volume>215</volume>:<page-range>243&#8211;53</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1600-065X.2006.00484.x</pub-id><pub-id pub-id-type="pmcid">PMC3864677</pub-id><pub-id pub-id-type="pmid">17291293</pub-id></mixed-citation></ref><ref id="B62"><label>62</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Danese</surname><given-names>S</given-names></name></person-group>. <article-title>Nonimmune cells in inflammatory bowel disease: from victim to villain</article-title>. <source>Trends Immunol</source> (<year>2008</year>) <volume>29</volume>:<page-range>555&#8211;64</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.it.2008.07.009</pub-id><pub-id pub-id-type="pmid">18838297</pub-id></mixed-citation></ref><ref id="B63"><label>63</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Morbe</surname><given-names>UM</given-names></name><name name-style="western"><surname>Jorgensen</surname><given-names>PB</given-names></name><name name-style="western"><surname>Fenton</surname><given-names>TM</given-names></name><name name-style="western"><surname>von Burg</surname><given-names>N</given-names></name><name name-style="western"><surname>Riis</surname><given-names>LB</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Human gut-associated lymphoid tissues (GALT); diversity, structure, and function</article-title>. <source>Mucosal Immunol</source> (<year>2021</year>) <volume>14</volume>:<fpage>793</fpage>&#8211;<lpage>802</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41385-021-00389-4</pub-id><pub-id pub-id-type="pmid">33753873</pub-id></mixed-citation></ref><ref id="B64"><label>64</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shamri</surname><given-names>R</given-names></name><name name-style="western"><surname>Xenakis</surname><given-names>JJ</given-names></name><name name-style="western"><surname>Spencer</surname><given-names>LA</given-names></name></person-group>. <article-title>Eosinophils in innate immunity: an evolving story</article-title>. <source>Cell Tissue Res</source> (<year>2011</year>) <volume>343</volume>:<fpage>57</fpage>&#8211;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00441-010-1049-6</pub-id><pub-id pub-id-type="pmid">21042920</pub-id><pub-id pub-id-type="pmcid">PMC3679536</pub-id></mixed-citation></ref><ref id="B65"><label>65</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chu</surname><given-names>VT</given-names></name><name name-style="western"><surname>Beller</surname><given-names>A</given-names></name><name name-style="western"><surname>Rausch</surname><given-names>S</given-names></name><name name-style="western"><surname>Strandmark</surname><given-names>J</given-names></name><name name-style="western"><surname>Z&#228;nker</surname><given-names>M</given-names></name><name name-style="western"><surname>Arbach</surname><given-names>O</given-names></name><etal/></person-group>. <article-title>Eosinophils promote generation and maintenance of immunoglobulin-a-expressing plasma cells and contribute to gut immune homeostasis</article-title>. <source>Immunity</source> (<year>2014</year>) <volume>40</volume>:<page-range>582&#8211;93</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2014.02.014</pub-id><pub-id pub-id-type="pmid">24745334</pub-id></mixed-citation></ref><ref id="B66"><label>66</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wu</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>BS</given-names></name><name name-style="western"><surname>He</surname><given-names>SH</given-names></name><name name-style="western"><surname>Zheng</surname><given-names>PY</given-names></name><name name-style="western"><surname>Croitoru</surname><given-names>K</given-names></name><name name-style="western"><surname>Yang</surname><given-names>PC</given-names></name></person-group>. <article-title>Bacterial peptidoglycan breaks down intestinal tolerance <italic toggle="yes">via</italic> mast cell activation: the role of TLR2 and NOD2</article-title>. <source>Immunol Cell Biol</source> (<year>2007</year>) <volume>85</volume>:<page-range>538&#8211;45</page-range>. doi: <pub-id pub-id-type="doi">10.1038/sj.icb.7100079</pub-id><pub-id pub-id-type="pmid">17563761</pub-id></mixed-citation></ref><ref id="B67"><label>67</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kadaoui</surname><given-names>KA</given-names></name><name name-style="western"><surname>Corthesy</surname><given-names>B</given-names></name></person-group>. <article-title>Secretory IgA mediates bacterial translocation to dendritic cells in mouse peyer's patches with restriction to mucosal compartment</article-title>. <source>J Immunol</source> (<year>2007</year>) <volume>179</volume>:<page-range>7751&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.179.11.7751</pub-id><pub-id pub-id-type="pmid">18025221</pub-id></mixed-citation></ref><ref id="B68"><label>68</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Godfrey</surname><given-names>DI</given-names></name><name name-style="western"><surname>Koay</surname><given-names>HF</given-names></name><name name-style="western"><surname>McCluskey</surname><given-names>J</given-names></name><name name-style="western"><surname>Gherardin</surname><given-names>NA</given-names></name></person-group>. <article-title>The biology and functional importance of MAIT cells</article-title>. <source>Nat Immunol</source> (<year>2019</year>) <volume>20</volume>:<page-range>1110&#8211;28</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41590-019-0444-8</pub-id><pub-id pub-id-type="pmid">31406380</pub-id></mixed-citation></ref><ref id="B69"><label>69</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Victor</surname><given-names>AR</given-names></name><name name-style="western"><surname>Nalin</surname><given-names>AP</given-names></name><name name-style="western"><surname>Dong</surname><given-names>W</given-names></name><name name-style="western"><surname>McClory</surname><given-names>S</given-names></name><name name-style="western"><surname>Wei</surname><given-names>M</given-names></name><name name-style="western"><surname>Mao</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>IL-18 drives ILC3 proliferation and promotes IL-22 production <italic toggle="yes">via</italic> NF-kappaB</article-title>. <source>J Immunol</source> (<year>2017</year>) <volume>199</volume>:<page-range>2333&#8211;42</page-range>. doi: <pub-id pub-id-type="doi">10.4049/jimmunol.1601554</pub-id><pub-id pub-id-type="pmcid">PMC5624342</pub-id><pub-id pub-id-type="pmid">28842466</pub-id></mixed-citation></ref><ref id="B70"><label>70</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Middendorp</surname><given-names>S</given-names></name><name name-style="western"><surname>Nieuwenhuis</surname><given-names>EE</given-names></name></person-group>. <article-title>NKT cells in mucosal immunity</article-title>. <source>Mucosal Immunol</source> (<year>2009</year>) <volume>2</volume>:<fpage>393</fpage>&#8211;<lpage>402</lpage>. doi: <pub-id pub-id-type="doi">10.1038/mi.2009.99</pub-id><pub-id pub-id-type="pmid">19587641</pub-id></mixed-citation></ref><ref id="B71"><label>71</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Edelblum</surname><given-names>KL</given-names></name><name name-style="western"><surname>Sharon</surname><given-names>G</given-names></name><name name-style="western"><surname>Singh</surname><given-names>G</given-names></name><name name-style="western"><surname>Odenwald</surname><given-names>MA</given-names></name><name name-style="western"><surname>Sailer</surname><given-names>A</given-names></name><name name-style="western"><surname>Cao</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>The microbiome activates CD4 T-cell-mediated immunity to compensate for increased intestinal permeability</article-title>. <source>Cell Mol Gastroenterol Hepatol</source> (<year>2017</year>) <volume>4</volume>:<page-range>285&#8211;97</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jcmgh.2017.06.001</pub-id><pub-id pub-id-type="pmcid">PMC5540699</pub-id><pub-id pub-id-type="pmid">28795125</pub-id></mixed-citation></ref><ref id="B72"><label>72</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bettelli</surname><given-names>E</given-names></name><name name-style="western"><surname>Carrier</surname><given-names>Y</given-names></name><name name-style="western"><surname>Gao</surname><given-names>W</given-names></name><name name-style="western"><surname>Korn</surname><given-names>T</given-names></name><name name-style="western"><surname>Strom</surname><given-names>TB</given-names></name><name name-style="western"><surname>Oukka</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Reciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cells</article-title>. <source>Nature</source> (<year>2006</year>) <volume>441</volume>:<page-range>235&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1038/nature04753</pub-id><pub-id pub-id-type="pmid">16648838</pub-id></mixed-citation></ref><ref id="B73"><label>73</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albillos</surname><given-names>A</given-names></name><name name-style="western"><surname>de Gottardi</surname><given-names>A</given-names></name><name name-style="western"><surname>Rescigno</surname><given-names>M</given-names></name></person-group>. <article-title>The gut-liver axis in liver disease: Pathophysiological basis for therapy</article-title>. <source>J Hepatol</source> (<year>2020</year>) <volume>72</volume>:<page-range>558&#8211;77</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2019.10.003</pub-id><pub-id pub-id-type="pmid">31622696</pub-id></mixed-citation></ref><ref id="B74"><label>74</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Yang</surname><given-names>X</given-names></name><name name-style="western"><surname>Lu</surname><given-names>D</given-names></name><name name-style="western"><surname>Zhuo</surname><given-names>J</given-names></name><name name-style="western"><surname>Lin</surname><given-names>Z</given-names></name><name name-style="western"><surname>Yang</surname><given-names>M</given-names></name><name name-style="western"><surname>Xu</surname><given-names>X</given-names></name></person-group>. <article-title>The gut-liver axis in immune remodeling: New insight into liver diseases</article-title>. <source>Int J Biol Sci</source> (<year>2020</year>) <volume>16</volume>:<page-range>2357&#8211;66</page-range>. doi: <pub-id pub-id-type="doi">10.7150/ijbs.46405</pub-id><pub-id pub-id-type="pmcid">PMC7378637</pub-id><pub-id pub-id-type="pmid">32760203</pub-id></mixed-citation></ref><ref id="B75"><label>75</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Spadoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Zagato</surname><given-names>E</given-names></name><name name-style="western"><surname>Bertocchi</surname><given-names>A</given-names></name><name name-style="western"><surname>Paolinelli</surname><given-names>R</given-names></name><name name-style="western"><surname>Hot</surname><given-names>E</given-names></name><name name-style="western"><surname>Di Sabatino</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>A gut-vascular barrier controls the systemic dissemination of bacteria</article-title>. <source>Science</source> (<year>2015</year>) <volume>350</volume>:<page-range>830&#8211;4</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.aad0135</pub-id><pub-id pub-id-type="pmid">26564856</pub-id></mixed-citation></ref><ref id="B76"><label>76</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tripathi</surname><given-names>A</given-names></name><name name-style="western"><surname>Debelius</surname><given-names>J</given-names></name><name name-style="western"><surname>Brenner</surname><given-names>DA</given-names></name><name name-style="western"><surname>Karin</surname><given-names>M</given-names></name><name name-style="western"><surname>Loomba</surname><given-names>R</given-names></name><name name-style="western"><surname>Schnabl</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>The gut-liver axis and the intersection with the microbiome</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> (<year>2018</year>) <volume>15</volume>:<fpage>397</fpage>&#8211;<lpage>411</lpage>. doi: <pub-id pub-id-type="doi">10.1038/s41575-018-0011-z</pub-id><pub-id pub-id-type="pmid">29748586</pub-id><pub-id pub-id-type="pmcid">PMC6319369</pub-id></mixed-citation></ref><ref id="B77"><label>77</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schaap</surname><given-names>FG</given-names></name><name name-style="western"><surname>Trauner</surname><given-names>M</given-names></name><name name-style="western"><surname>Jansen</surname><given-names>PL</given-names></name></person-group>. <article-title>Bile acid receptors as targets for drug development</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> (<year>2014</year>) <volume>11</volume>:<fpage>55</fpage>&#8211;<lpage>67</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrgastro.2013.151</pub-id><pub-id pub-id-type="pmid">23982684</pub-id></mixed-citation></ref><ref id="B78"><label>78</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wang</surname><given-names>YD</given-names></name><name name-style="western"><surname>Chen</surname><given-names>WD</given-names></name><name name-style="western"><surname>Yu</surname><given-names>D</given-names></name><name name-style="western"><surname>Forman</surname><given-names>BM</given-names></name><name name-style="western"><surname>Huang</surname><given-names>W</given-names></name></person-group>. <article-title>The G-protein-coupled bile acid receptor, Gpbar1 (TGR5), negatively regulates hepatic inflammatory response through antagonizing nuclear factor kappa light-chain enhancer of activated b cells (NF-kappaB) in mice</article-title>. <source>Hepatology</source> (<year>2011</year>) <volume>54</volume>:<page-range>1421&#8211;32</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.24525</pub-id><pub-id pub-id-type="pmcid">PMC3184183</pub-id><pub-id pub-id-type="pmid">21735468</pub-id></mixed-citation></ref><ref id="B79"><label>79</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ridlon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>DJ</given-names></name><name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></name><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name></person-group>. <article-title>Bile acids and the gut microbiome</article-title>. <source>Curr Opin Gastroenterol</source> (<year>2014</year>) <volume>30</volume>:<page-range>332&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1097/MOG.0000000000000057</pub-id><pub-id pub-id-type="pmcid">PMC4215539</pub-id><pub-id pub-id-type="pmid">24625896</pub-id></mixed-citation></ref><ref id="B80"><label>80</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Begley</surname><given-names>M</given-names></name><name name-style="western"><surname>Gahan</surname><given-names>CG</given-names></name><name name-style="western"><surname>Hill</surname><given-names>C</given-names></name></person-group>. <article-title>The interaction between bacteria and bile</article-title>. <source>FEMS Microbiol Rev</source> (<year>2005</year>) <volume>29</volume>:<page-range>625&#8211;51</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.femsre.2004.09.003</pub-id><pub-id pub-id-type="pmid">16102595</pub-id></mixed-citation></ref><ref id="B81"><label>81</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Inamine</surname><given-names>T</given-names></name><name name-style="western"><surname>Schnabl</surname><given-names>B</given-names></name></person-group>. <article-title>Immunoglobulin a and liver diseases</article-title>. <source>J Gastroenterol</source> (<year>2018</year>) <volume>53</volume>:<fpage>691</fpage>&#8211;<lpage>700</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00535-017-1400-8</pub-id><pub-id pub-id-type="pmid">29075899</pub-id><pub-id pub-id-type="pmcid">PMC5971039</pub-id></mixed-citation></ref><ref id="B82"><label>82</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gutzeit</surname><given-names>C</given-names></name><name name-style="western"><surname>Magri</surname><given-names>G</given-names></name><name name-style="western"><surname>Cerutti</surname><given-names>A</given-names></name></person-group>. <article-title>Intestinal IgA production and its role in host-microbe interaction</article-title>. <source>Immunol Rev</source> (<year>2014</year>) <volume>260</volume>:<fpage>76</fpage>&#8211;<lpage>85</lpage>. doi: <pub-id pub-id-type="doi">10.1111/imr.12189</pub-id><pub-id pub-id-type="pmid">24942683</pub-id><pub-id pub-id-type="pmcid">PMC4174397</pub-id></mixed-citation></ref><ref id="B83"><label>83</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Suzuki</surname><given-names>K</given-names></name><name name-style="western"><surname>Meek</surname><given-names>B</given-names></name><name name-style="western"><surname>Doi</surname><given-names>Y</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>KV</given-names></name><name name-style="western"><surname>Bastiaanssen</surname><given-names>TFS</given-names></name><name name-style="western"><surname>Boehme</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Aberrant expansion of segmented filamentous bacteria in IgA-deficient gut</article-title>. <source>Proc Natl Acad Sci U.S.A.</source> (<year>2004</year>) <volume>101</volume>:<page-range>1981&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1073/pnas.0307317101</pub-id><pub-id pub-id-type="pmcid">PMC357038</pub-id><pub-id pub-id-type="pmid">14766966</pub-id></mixed-citation></ref><ref id="B84"><label>84</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cryan</surname><given-names>JF</given-names></name><name name-style="western"><surname>O'Riordan</surname><given-names>KJ</given-names></name><name name-style="western"><surname>Cowan</surname><given-names>CSM</given-names></name><name name-style="western"><surname>Sandhu</surname><given-names>KV</given-names></name><name name-style="western"><surname>Bastiaanssen</surname><given-names>TFS</given-names></name><name name-style="western"><surname>Boehme</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The microbiota-Gut-Brain axis</article-title>. <source>Physiol Rev</source> (<year>2019</year>) <volume>99</volume>:<fpage>1877</fpage>&#8211;<lpage>2013</lpage>. doi: <pub-id pub-id-type="doi">10.1152/physrev.00018.2018</pub-id><pub-id pub-id-type="pmid">31460832</pub-id></mixed-citation></ref><ref id="B85"><label>85</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Agirman</surname><given-names>G</given-names></name><name name-style="western"><surname>Yu</surname><given-names>KB</given-names></name><name name-style="western"><surname>Hsiao</surname><given-names>EY</given-names></name></person-group>. <article-title>Signaling inflammation across the gut-brain axis</article-title>. <source>Science</source> (<year>2021</year>) <volume>374</volume>:<page-range>1087&#8211;92</page-range>. doi: <pub-id pub-id-type="doi">10.1126/science.abi6087</pub-id><pub-id pub-id-type="pmid">34822299</pub-id></mixed-citation></ref><ref id="B86"><label>86</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xu</surname><given-names>C</given-names></name><name name-style="western"><surname>Lee</surname><given-names>SK</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>D</given-names></name><name name-style="western"><surname>Frenette</surname><given-names>PS</given-names></name></person-group>. <article-title>The gut microbiome regulates psychological-Stress-Induced inflammation</article-title>. <source>Immunity</source> (<year>2020</year>) <volume>53</volume>:<fpage>417</fpage>&#8211;<lpage>428 e4</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2020.06.025</pub-id><pub-id pub-id-type="pmid">32735844</pub-id><pub-id pub-id-type="pmcid">PMC7461158</pub-id></mixed-citation></ref><ref id="B87"><label>87</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albillos</surname><given-names>A</given-names></name><name name-style="western"><surname>de la</surname><given-names>HA</given-names></name></person-group>. <article-title>Multifactorial gut barrier failure in cirrhosis and bacterial translocation: working out the role of probiotics and antioxidants</article-title>. <source>J.Hepatol</source> (<year>2002</year>) <volume>37</volume>:<fpage>523</fpage>. doi: <pub-id pub-id-type="doi">10.1016/S0168-8278(02)00265-9</pub-id><pub-id pub-id-type="pmid">12217607</pub-id></mixed-citation></ref><ref id="B88"><label>88</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Perez-Paramo</surname><given-names>M</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>J</given-names></name><name name-style="western"><surname>Albillos</surname><given-names>A</given-names></name><name name-style="western"><surname>Freile</surname><given-names>I</given-names></name><name name-style="western"><surname>Portero</surname><given-names>F</given-names></name><name name-style="western"><surname>Santos</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites</article-title>. <source>Hepatology</source> (<year>2000</year>) <volume>31</volume>:<page-range>43&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.510310109</pub-id><pub-id pub-id-type="pmid">10613726</pub-id></mixed-citation></ref><ref id="B89"><label>89</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Yang</surname><given-names>F</given-names></name><name name-style="western"><surname>Lu</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>B</given-names></name><name name-style="western"><surname>Chen</surname><given-names>Y</given-names></name><name name-style="western"><surname>Lei</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Characterization of fecal microbial communities in patients with liver cirrhosis</article-title>. <source>Hepatology</source> (<year>2011</year>) <volume>54</volume>:<page-range>562&#8211;72</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.24423</pub-id><pub-id pub-id-type="pmid">21574172</pub-id></mixed-citation></ref><ref id="B90"><label>90</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></name><name name-style="western"><surname>Ridlon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Heuman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Daita</surname><given-names>K</given-names></name><name name-style="western"><surname>White</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Colonic mucosal microbiome differs from stool microbiome in cirrhosis and hepatic encephalopathy and is linked to cognition and inflammation</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> (<year>2012</year>) <volume>303</volume>:<page-range>G675&#8211;85</page-range>. doi: <pub-id pub-id-type="doi">10.1152/ajpgi.00152.2012</pub-id><pub-id pub-id-type="pmcid">PMC3468538</pub-id><pub-id pub-id-type="pmid">22821944</pub-id></mixed-citation></ref><ref id="B91"><label>91</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><name name-style="western"><surname>Heuman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>AJ</given-names></name><name name-style="western"><surname>White</surname><given-names>MB</given-names></name><name name-style="western"><surname>Monteith</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Altered profile of human gut microbiome is associated with cirrhosis and its complications</article-title>. <source>J Hepatol</source> (<year>2014</year>) <volume>60</volume>:<page-range>940&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2013.12.019</pub-id><pub-id pub-id-type="pmcid">PMC3995845</pub-id><pub-id pub-id-type="pmid">24374295</pub-id></mixed-citation></ref><ref id="B92"><label>92</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gunnarsdottir</surname><given-names>SA</given-names></name><name name-style="western"><surname>Sadik</surname><given-names>R</given-names></name><name name-style="western"><surname>Shev</surname><given-names>S</given-names></name><name name-style="western"><surname>Simr&#233;n</surname><given-names>M</given-names></name><name name-style="western"><surname>Sj&#246;vall</surname><given-names>H</given-names></name><name name-style="western"><surname>Stotzer</surname><given-names>PO</given-names></name><etal/></person-group>. <article-title>Small intestinal motility disturbances and bacterial overgrowth in patients with liver cirrhosis and portal hypertension</article-title>. <source>Am J Gastroenterol</source> (<year>2003</year>) <volume>98</volume>:<page-range>1362&#8211;70</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1572-0241.2003.07475.x</pub-id><pub-id pub-id-type="pmid">12818282</pub-id></mixed-citation></ref><ref id="B93"><label>93</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Lorenzo-Zuniga</surname><given-names>V</given-names></name><name name-style="western"><surname>Bartoli</surname><given-names>R</given-names></name><name name-style="western"><surname>Planas</surname><given-names>R</given-names></name><name name-style="western"><surname>Hofmann</surname><given-names>AF</given-names></name><name name-style="western"><surname>Vi&#241;ado</surname><given-names>B</given-names></name><name name-style="western"><surname>Hagey</surname><given-names>LR</given-names></name><etal/></person-group>. <article-title>Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats</article-title>. <source>Hepatology</source> (<year>2003</year>) <volume>37</volume>:<page-range>551&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1053/jhep.2003.50116</pub-id><pub-id pub-id-type="pmid">12601352</pub-id></mixed-citation></ref><ref id="B94"><label>94</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakiyama</surname><given-names>G</given-names></name><name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>H</given-names></name><name name-style="western"><surname>Pandak</surname><given-names>WM</given-names></name><name name-style="western"><surname>Heuman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Kang</surname><given-names>DJ</given-names></name><etal/></person-group>. <article-title>Colonic inflammation and secondary bile acids in alcoholic cirrhosis</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> (<year>2014</year>) <volume>306</volume>:<page-range>G929&#8211;37</page-range>. doi: <pub-id pub-id-type="doi">10.1152/ajpgi.00315.2013</pub-id><pub-id pub-id-type="pmcid">PMC4152166</pub-id><pub-id pub-id-type="pmid">24699327</pub-id></mixed-citation></ref><ref id="B95"><label>95</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Kakiyama</surname><given-names>G</given-names></name><name name-style="western"><surname>Pandak</surname><given-names>WM</given-names></name><name name-style="western"><surname>Gillevet</surname><given-names>PM</given-names></name><name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></name><name name-style="western"><surname>Heuman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Daita</surname><given-names>K</given-names></name><etal/></person-group>. <article-title>Modulation of the fecal bile acid profile by gut microbiota in cirrhosis</article-title>. <source>J Hepatol</source> (<year>2013</year>) <volume>58</volume>:<page-range>949&#8211;55</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2013.01.003</pub-id><pub-id pub-id-type="pmcid">PMC3936319</pub-id><pub-id pub-id-type="pmid">23333527</pub-id></mixed-citation></ref><ref id="B96"><label>96</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jakobsson</surname><given-names>HE</given-names></name><name name-style="western"><surname>Rodriguez-Pineiro</surname><given-names>AM</given-names></name><name name-style="western"><surname>Schutte</surname><given-names>A</given-names></name><name name-style="western"><surname>Ermund</surname><given-names>A</given-names></name><name name-style="western"><surname>Boysen</surname><given-names>P</given-names></name><name name-style="western"><surname>Bemark</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>The composition of the gut microbiota shapes the colon mucus barrier</article-title>. <source>EMBO Rep</source> (<year>2015</year>) <volume>16</volume>:<page-range>164&#8211;77</page-range>. doi: <pub-id pub-id-type="doi">10.15252/embr.201439263</pub-id><pub-id pub-id-type="pmcid">PMC4328744</pub-id><pub-id pub-id-type="pmid">25525071</pub-id></mixed-citation></ref><ref id="B97"><label>97</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Such</surname><given-names>J</given-names></name><name name-style="western"><surname>Guardiola</surname><given-names>JV</given-names></name><name name-style="western"><surname>de Juan</surname><given-names>J</given-names></name><name name-style="western"><surname>Casellas</surname><given-names>JA</given-names></name><name name-style="western"><surname>Pascual</surname><given-names>S</given-names></name><name name-style="western"><surname>Aparicio</surname><given-names>JR</given-names></name><etal/></person-group>. <article-title>Ultrastructural characteristics of distal duodenum mucosa in patients with cirrhosis</article-title>. <source>Eur.J Gastroenterol Hepatol</source> (<year>2002</year>) <volume>14</volume>:<page-range>371&#8211;6</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1097/00042737-200204000-00006</pub-id><pub-id pub-id-type="pmid">11943948</pub-id></mixed-citation></ref><ref id="B98"><label>98</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assimakopoulos</surname><given-names>SF</given-names></name><name name-style="western"><surname>Tsamandas</surname><given-names>AC</given-names></name><name name-style="western"><surname>Tsiaoussis</surname><given-names>GI</given-names></name><name name-style="western"><surname>Karatza</surname><given-names>E</given-names></name><name name-style="western"><surname>Triantos</surname><given-names>C</given-names></name><name name-style="western"><surname>Vagianos</surname><given-names>CE</given-names></name><etal/></person-group>. <article-title>Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenetic mechanism of intestinal hyperpermeability</article-title>. <source>Eur J Clin Invest</source> (<year>2012</year>) <volume>42</volume>:<page-range>439&#8211;46</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2362.2011.02609.x</pub-id><pub-id pub-id-type="pmid">22023490</pub-id></mixed-citation></ref><ref id="B99"><label>99</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Assimakopoulos</surname><given-names>SF</given-names></name><name name-style="western"><surname>Tsamandas</surname><given-names>AC</given-names></name><name name-style="western"><surname>Tsiaoussis</surname><given-names>GI</given-names></name><name name-style="western"><surname>Karatza</surname><given-names>E</given-names></name><name name-style="western"><surname>Zisimopoulos</surname><given-names>D</given-names></name><name name-style="western"><surname>Maroulis</surname><given-names>I</given-names></name><etal/></person-group>. <article-title>Intestinal mucosal proliferation, apoptosis and oxidative stress in patients with liver cirrhosis</article-title>. <source>Ann Hepatol</source> (<year>2013</year>) <volume>12</volume>:<page-range>301&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S1665-2681(19)31369-9</pub-id><pub-id pub-id-type="pmid">23396742</pub-id></mixed-citation></ref><ref id="B100"><label>100</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ramachandran</surname><given-names>A</given-names></name><name name-style="western"><surname>Prabhu</surname><given-names>R</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Reddy</surname><given-names>JB</given-names></name><name name-style="western"><surname>Pulimood</surname><given-names>A</given-names></name><name name-style="western"><surname>Balasubramanian</surname><given-names>KA</given-names></name></person-group>. <article-title>Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals</article-title>. <source>Hepatology</source> (<year>2002</year>) <volume>35</volume>:<page-range>622&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1053/jhep.2002.31656</pub-id><pub-id pub-id-type="pmid">11870376</pub-id></mixed-citation></ref><ref id="B101"><label>101</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Natarajan</surname><given-names>SK</given-names></name><name name-style="western"><surname>Ramamoorthy</surname><given-names>P</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>S</given-names></name><name name-style="western"><surname>Basivireddy</surname><given-names>J</given-names></name><name name-style="western"><surname>Kang</surname><given-names>G</given-names></name><name name-style="western"><surname>Ramachandran</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Intestinal mucosal alterations in rats with carbon tetrachloride-induced cirrhosis: changes in glycosylation and luminal bacteria</article-title>. <source>Hepatology</source> (<year>2006</year>) <volume>43</volume>:<page-range>837&#8211;46</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.21097</pub-id><pub-id pub-id-type="pmid">16557555</pub-id></mixed-citation></ref><ref id="B102"><label>102</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Gao</surname><given-names>JH</given-names></name><name name-style="western"><surname>Wen</surname><given-names>SL</given-names></name><name name-style="western"><surname>Tong</surname><given-names>H</given-names></name><name name-style="western"><surname>Wang</surname><given-names>CH</given-names></name><name name-style="western"><surname>Yang</surname><given-names>WJ</given-names></name><name name-style="western"><surname>Tang</surname><given-names>SH</given-names></name><etal/></person-group>. <article-title>Inhibition of cyclooxygenase-2 alleviates liver cirrhosis via improvement of the dysfunctional gut-liver axis in rats</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> (<year>2016</year>) <volume>310</volume>:<page-range>G962&#8211;72</page-range>. doi: <pub-id pub-id-type="doi">10.1152/ajpgi.00428.2015</pub-id><pub-id pub-id-type="pmid">27056726</pub-id></mixed-citation></ref><ref id="B103"><label>103</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Mouries</surname><given-names>J</given-names></name><name name-style="western"><surname>Brescia</surname><given-names>P</given-names></name><name name-style="western"><surname>Silvestri</surname><given-names>A</given-names></name><name name-style="western"><surname>Spadoni</surname><given-names>I</given-names></name><name name-style="western"><surname>Sorribas</surname><given-names>M</given-names></name><name name-style="western"><surname>Wiest</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Microbiota-driven gut vascular barrier disruption is a prerequisite for non-alcoholic steatohepatitis development</article-title>. <source>J Hepatol</source> (<year>2019</year>) <volume>71</volume>:<page-range>1216&#8211;28</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2019.08.005</pub-id><pub-id pub-id-type="pmcid">PMC6880766</pub-id><pub-id pub-id-type="pmid">31419514</pub-id></mixed-citation></ref><ref id="B104"><label>104</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Tsiaoussis</surname><given-names>GI</given-names></name><name name-style="western"><surname>Papaioannou</surname><given-names>EC</given-names></name><name name-style="western"><surname>Kourea</surname><given-names>EP</given-names></name><name name-style="western"><surname>Assimakopoulos</surname><given-names>SF</given-names></name><name name-style="western"><surname>Theocharis</surname><given-names>GI</given-names></name><name name-style="western"><surname>Petropoulos</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Expression of alpha-defensins, CD20+ b-lymphocytes, and intraepithelial CD3+ T-lymphocytes in the intestinal mucosa of patients with liver cirrhosis: Emerging mediators of intestinal barrier function</article-title>. <source>Dig Dis Sci</source> (<year>2018</year>) <volume>63</volume>:<page-range>2582&#8211;92</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s10620-018-5146-9</pub-id><pub-id pub-id-type="pmid">29876779</pub-id></mixed-citation></ref><ref id="B105"><label>105</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Urdaneta</surname><given-names>V</given-names></name><name name-style="western"><surname>Casadesus</surname><given-names>J</given-names></name></person-group>. <article-title>Interactions between bacteria and bile salts in the gastrointestinal and hepatobiliary tracts</article-title>. <source>Front Med (Lausanne)</source> (<year>2017</year>) <volume>4</volume>:<elocation-id>163</elocation-id>. doi: <pub-id pub-id-type="doi">10.3389/fmed.2017.00163</pub-id><pub-id pub-id-type="pmid">29043249</pub-id><pub-id pub-id-type="pmcid">PMC5632352</pub-id></mixed-citation></ref><ref id="B106"><label>106</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Sun</surname><given-names>D</given-names></name><name name-style="western"><surname>Bai</surname><given-names>R</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>W</given-names></name><name name-style="western"><surname>Yao</surname><given-names>Z</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Tang</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Angiogenin maintains gut microbe homeostasis by balancing alpha-proteobacteria and lachnospiraceae</article-title>. <source>Gut</source> (<year>2021</year>) <volume>70</volume>:<page-range>666&#8211;76</page-range>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2019-320135</pub-id><pub-id pub-id-type="pmcid">PMC7904960</pub-id><pub-id pub-id-type="pmid">32843357</pub-id></mixed-citation></ref><ref id="B107"><label>107</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Munoz</surname><given-names>L</given-names></name><name name-style="western"><surname>Albillos</surname><given-names>A</given-names></name><name name-style="western"><surname>Nieto</surname><given-names>M</given-names></name><name name-style="western"><surname>Reyes</surname><given-names>E</given-names></name><name name-style="western"><surname>Lled&#243;</surname><given-names>L</given-names></name><name name-style="western"><surname>Monserrat</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Mesenteric Th1 polarization and monocyte TNF-&#945; production: first steps to systemic inflammation in rats with cirrhosis</article-title>. <source>Hepatology</source> (<year>2005</year>) <volume>42</volume>:<page-range>411&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.20799</pub-id><pub-id pub-id-type="pmid">16025514</pub-id></mixed-citation></ref><ref id="B108"><label>108</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ubeda</surname><given-names>M</given-names></name><name name-style="western"><surname>Munoz</surname><given-names>L</given-names></name><name name-style="western"><surname>Borrero</surname><given-names>MJ</given-names></name><name name-style="western"><surname>D&#237;az</surname><given-names>D</given-names></name><name name-style="western"><surname>Franc&#233;s</surname><given-names>R</given-names></name><name name-style="western"><surname>Monserrat</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Critical role of the liver in the induction of systemic inflammation in rats with preascitic cirrhosis</article-title>. <source>Hepatology</source> (<year>2010</year>) <volume>52</volume>:<page-range>2086&#8211;95</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.23961</pub-id><pub-id pub-id-type="pmid">21105108</pub-id></mixed-citation></ref><ref id="B109"><label>109</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Liu</surname><given-names>L</given-names></name><name name-style="western"><surname>Zhang</surname><given-names>C</given-names></name><name name-style="western"><surname>Hu</surname><given-names>Y</given-names></name><name name-style="western"><surname>Zhou</surname><given-names>L</given-names></name><name name-style="western"><surname>Tan</surname><given-names>Q</given-names></name></person-group>. <article-title>Changes in gut toll-like receptor-4 and nod-like receptor family pyrin domain containing-3 innate pathways in liver cirrhosis rats with bacterial translocation</article-title>. <source>Clin Res Hepatol Gastroenterol</source> (<year>2016</year>) <volume>40</volume>:<page-range>575&#8211;83</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.clinre.2016.02.008</pub-id><pub-id pub-id-type="pmid">27061671</pub-id></mixed-citation></ref><ref id="B110"><label>110</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Genesca</surname><given-names>J</given-names></name><name name-style="western"><surname>Marti</surname><given-names>R</given-names></name><name name-style="western"><surname>Rojo</surname><given-names>F</given-names></name><name name-style="western"><surname>Campos</surname><given-names>F</given-names></name><name name-style="western"><surname>Perib&#225;&#241;ez</surname><given-names>V</given-names></name><name name-style="western"><surname>G&#243;nzalez</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Increased tumour necrosis factor alpha production in mesenteric lymph nodes of cirrhotic patients with ascites</article-title>. <source>Gut</source> (<year>2003</year>) <volume>52</volume>:<page-range>1054&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1136/gut.52.7.1054</pub-id><pub-id pub-id-type="pmcid">PMC1773719</pub-id><pub-id pub-id-type="pmid">12801966</pub-id></mixed-citation></ref><ref id="B111"><label>111</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albillos</surname><given-names>A</given-names></name><name name-style="western"><surname>Martin-Mateos</surname><given-names>R</given-names></name><name name-style="western"><surname>van der Merwe</surname><given-names>S</given-names></name><name name-style="western"><surname>Wiest</surname><given-names>R</given-names></name><name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name><name name-style="western"><surname>&#193;lvarez-Mon</surname><given-names>M</given-names></name></person-group>. <article-title>Cirrhosis-associated immune dysfunction</article-title>. <source>Nat Rev Gastroenterol Hepatol</source> (<year>2022</year>) <volume>19</volume>:<page-range>112&#8211;34</page-range>. doi: <pub-id pub-id-type="doi">10.1038/s41575-021-00520-7</pub-id><pub-id pub-id-type="pmid">34703031</pub-id></mixed-citation></ref><ref id="B112"><label>112</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Albillos</surname><given-names>A</given-names></name><name name-style="western"><surname>de la</surname><given-names>HA</given-names></name><name name-style="western"><surname>Gonzalez</surname><given-names>M</given-names></name><name name-style="western"><surname>Moya</surname><given-names>JL</given-names></name><name name-style="western"><surname>Calleja</surname><given-names>JL</given-names></name><name name-style="western"><surname>Monserrat</surname><given-names>J</given-names></name><etal/></person-group>. <article-title>Increased lipopolysaccharide binding protein in cirrhotic patients with marked immune and hemodynamic derangement</article-title>. <source>Hepatology</source> (<year>2003</year>) <volume>37</volume>:<page-range>208&#8211;17</page-range>. doi: <pub-id pub-id-type="doi">10.1053/jhep.2003.50038</pub-id><pub-id pub-id-type="pmid">12500206</pub-id></mixed-citation></ref><ref id="B113"><label>113</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Schierwagen</surname><given-names>R</given-names></name><name name-style="western"><surname>Alvarez-Silva</surname><given-names>C</given-names></name><name name-style="western"><surname>Madsen</surname><given-names>MSA</given-names></name><name name-style="western"><surname>Kolbe</surname><given-names>CC</given-names></name><name name-style="western"><surname>Meyer</surname><given-names>C</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Circulating microbiome in blood of different circulatory compartments</article-title>. <source>Gut</source> (<year>2019</year>) <volume>68</volume>:<page-range>578&#8211;80</page-range>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2018-316227</pub-id><pub-id pub-id-type="pmid">29581241</pub-id></mixed-citation></ref><ref id="B114"><label>114</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Utech</surname><given-names>M</given-names></name><name name-style="western"><surname>Ivanov</surname><given-names>AI</given-names></name><name name-style="western"><surname>Samarin</surname><given-names>SN</given-names></name><name name-style="western"><surname>Bruewer</surname><given-names>M</given-names></name><name name-style="western"><surname>Turner</surname><given-names>JR</given-names></name><name name-style="western"><surname>Mrsny</surname><given-names>RJ</given-names></name><etal/></person-group>. <article-title>Mechanism of IFN-&#947;-induced endocytosis of tight junction proteins: myosin II-dependent vacuolarization of the apical plasma membrane</article-title>. <source>Mol Biol Cell</source> (<year>2005</year>) <volume>16</volume>:<page-range>5040&#8211;52</page-range>. doi: <pub-id pub-id-type="doi">10.1091/mbc.e05-03-0193</pub-id><pub-id pub-id-type="pmcid">PMC1237102</pub-id><pub-id pub-id-type="pmid">16055505</pub-id></mixed-citation></ref><ref id="B115"><label>115</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Guglani</surname><given-names>L</given-names></name><name name-style="western"><surname>Khader</surname><given-names>SA</given-names></name></person-group>. <article-title>Th17 cytokines in mucosal immunity and inflammation</article-title>. <source>Curr Opin HIV AIDS</source> (<year>2010</year>) <volume>5</volume>:<page-range>120&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1097/COH.0b013e328335c2f6</pub-id><pub-id pub-id-type="pmcid">PMC2892849</pub-id><pub-id pub-id-type="pmid">20543588</pub-id></mixed-citation></ref><ref id="B116"><label>116</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><name name-style="western"><surname>Hafeezullah</surname><given-names>M</given-names></name><name name-style="western"><surname>Hoffmann</surname><given-names>RG</given-names></name><name name-style="western"><surname>Varma</surname><given-names>RR</given-names></name><name name-style="western"><surname>Franco</surname><given-names>J</given-names></name><name name-style="western"><surname>Binion</surname><given-names>DG</given-names></name><etal/></person-group>. <article-title>Navigation skill impairment: Another dimension of the driving difficulties in minimal hepatic encephalopathy</article-title>. <source>Hepatology</source> (<year>2008</year>) <volume>47</volume>:<fpage>596</fpage>&#8211;<lpage>604</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hep.22032</pub-id><pub-id pub-id-type="pmid">18000989</pub-id></mixed-citation></ref><ref id="B117"><label>117</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Romero-Gomez</surname><given-names>M</given-names></name><name name-style="western"><surname>Boza</surname><given-names>F</given-names></name><name name-style="western"><surname>Garcia-Valdecasas</surname><given-names>MS</given-names></name><name name-style="western"><surname>Garc&#237;a</surname><given-names>E</given-names></name><name name-style="western"><surname>Aguilar-Reina</surname><given-names>J</given-names></name></person-group>. <article-title>Subclinical hepatic encephalopathy predicts the development of overt hepatic encephalopathy</article-title>. <source>Am J Gastroenterol</source> (<year>2001</year>) <volume>96</volume>:<page-range>2718&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.1016/S0002-9270(01)02692-2</pub-id><pub-id pub-id-type="pmid">11569701</pub-id></mixed-citation></ref><ref id="B118"><label>118</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butterworth</surname><given-names>RF</given-names></name></person-group>. <article-title>Hepatic encephalopathy in cirrhosis: Pathology and pathophysiology</article-title>. <source>Drugs</source> (<year>2019</year>) <volume>79</volume>:<fpage>17</fpage>&#8211;<lpage>21</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s40265-018-1017-0</pub-id><pub-id pub-id-type="pmid">30706423</pub-id><pub-id pub-id-type="pmcid">PMC6416236</pub-id></mixed-citation></ref><ref id="B119"><label>119</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Ezaz</surname><given-names>G</given-names></name><name name-style="western"><surname>Murphy</surname><given-names>SL</given-names></name><name name-style="western"><surname>Mellinger</surname><given-names>J</given-names></name><name name-style="western"><surname>Tapper</surname><given-names>EB</given-names></name></person-group>. <article-title>Increased morbidity and mortality associated with falls among patients with cirrhosis</article-title>. <source>Am J Med</source> (<year>2018</year>) <volume>131</volume>:<fpage>645</fpage>&#8211;<lpage>650 e2</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.amjmed.2018.01.026</pub-id><pub-id pub-id-type="pmid">29453941</pub-id></mixed-citation></ref><ref id="B120"><label>120</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butterworth</surname><given-names>RF</given-names></name><name name-style="western"><surname>Giguere</surname><given-names>JF</given-names></name><name name-style="western"><surname>Michaud</surname><given-names>J</given-names></name><name name-style="western"><surname>Lavoie</surname><given-names>J</given-names></name><name name-style="western"><surname>Layrargues</surname><given-names>GP</given-names></name></person-group>. <article-title>Ammonia: key factor in the pathogenesis of hepatic encephalopathy</article-title>. <source>Neurochem Pathol</source> (<year>1987</year>) <volume>6</volume>:<fpage>1</fpage>&#8211;<lpage>12</lpage>. doi: <pub-id pub-id-type="doi">10.1007/BF02833598</pub-id><pub-id pub-id-type="pmid">3306479</pub-id></mixed-citation></ref><ref id="B121"><label>121</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Butterworth</surname><given-names>RF</given-names></name></person-group>. <article-title>Hepatic encephalopathy: a central neuroinflammatory disorder</article-title>? <source>Hepatology</source> (<year>2011</year>) <volume>53</volume>:<page-range>1372&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.24228</pub-id><pub-id pub-id-type="pmid">21480337</pub-id></mixed-citation></ref><ref id="B122"><label>122</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shawcross</surname><given-names>DL</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NA</given-names></name><name name-style="western"><surname>Williams</surname><given-names>R</given-names></name><name name-style="western"><surname>Jalan</surname><given-names>R</given-names></name></person-group>. <article-title>Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis</article-title>. <source>J Hepatol</source> (<year>2004</year>) <volume>40</volume>:<page-range>247&#8211;54</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2003.10.016</pub-id><pub-id pub-id-type="pmid">14739095</pub-id></mixed-citation></ref><ref id="B123"><label>123</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wright</surname><given-names>G</given-names></name><name name-style="western"><surname>Davies</surname><given-names>NA</given-names></name><name name-style="western"><surname>Shawcross</surname><given-names>DL</given-names></name><name name-style="western"><surname>Hodges</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Zwingmann</surname><given-names>C</given-names></name><name name-style="western"><surname>Brooks</surname><given-names>HF</given-names></name></person-group>. <article-title>Endotoxemia produces coma and brain swelling in bile duct ligated rats</article-title>. <source>Hepatology</source> (<year>2007</year>) <volume>45</volume>:<page-range>1517&#8211;26</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.21599</pub-id><pub-id pub-id-type="pmid">17523148</pub-id></mixed-citation></ref><ref id="B124"><label>124</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Jain</surname><given-names>L</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>BC</given-names></name><name name-style="western"><surname>Srivastava</surname><given-names>S</given-names></name><name name-style="western"><surname>Puri</surname><given-names>SK</given-names></name><name name-style="western"><surname>Sharma</surname><given-names>P</given-names></name><name name-style="western"><surname>Sarin</surname><given-names>S</given-names></name></person-group>. <article-title>Serum endotoxin, inflammatory mediators, and magnetic resonance spectroscopy before and after treatment in patients with minimal hepatic encephalopathy</article-title>. <source>J Gastroenterol Hepatol</source> (<year>2013</year>) <volume>28</volume>:<page-range>1187&#8211;93</page-range>. doi: <pub-id pub-id-type="doi">10.1111/jgh.12160</pub-id><pub-id pub-id-type="pmid">23425082</pub-id></mixed-citation></ref><ref id="B125"><label>125</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Srivastava</surname><given-names>A</given-names></name><name name-style="western"><surname>Yadav</surname><given-names>SK</given-names></name><name name-style="western"><surname>Yachha</surname><given-names>SK</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>MA</given-names></name><name name-style="western"><surname>Saraswat</surname><given-names>VA</given-names></name><name name-style="western"><surname>Gupta</surname><given-names>RK</given-names></name></person-group>. <article-title>Pro-inflammatory cytokines are raised in extrahepatic portal venous obstruction, with minimal hepatic encephalopathy</article-title>. <source>J Gastroenterol Hepatol</source> (<year>2011</year>) <volume>26</volume>:<page-range>979&#8211;86</page-range>. doi: <pub-id pub-id-type="doi">10.1111/j.1440-1746.2011.06706.x</pub-id><pub-id pub-id-type="pmid">21362045</pub-id></mixed-citation></ref><ref id="B126"><label>126</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Shawcross</surname><given-names>DL</given-names></name><name name-style="western"><surname>Shabbir</surname><given-names>SS</given-names></name><name name-style="western"><surname>Taylor</surname><given-names>NJ</given-names></name><name name-style="western"><surname>Hughes</surname><given-names>RD</given-names></name></person-group>. <article-title>Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis</article-title>. <source>Hepatology</source> (<year>2010</year>) <volume>51</volume>:<page-range>1062&#8211;9</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.23367</pub-id><pub-id pub-id-type="pmid">19890967</pub-id></mixed-citation></ref><ref id="B127"><label>127</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Wunsch</surname><given-names>E</given-names></name><name name-style="western"><surname>Koziarska</surname><given-names>D</given-names></name><name name-style="western"><surname>Milkiewicz</surname><given-names>M</given-names></name><name name-style="western"><surname>Naprawa</surname><given-names>G</given-names></name><name name-style="western"><surname>Nowacki</surname><given-names>P</given-names></name><name name-style="western"><surname>Hartleb</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>In patients with liver cirrhosis, proinflammatory interleukins correlate with health-related quality of life irrespective of minimal hepatic encephalopathy</article-title>. <source>Eur J Gastroenterol Hepatol</source> (<year>2013</year>) <volume>25</volume>:<page-range>1402&#8211;7</page-range>. doi: <pub-id pub-id-type="doi">10.1097/MEG.0b013e328365a447</pub-id><pub-id pub-id-type="pmid">24025977</pub-id></mixed-citation></ref><ref id="B128"><label>128</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><name name-style="western"><surname>Ridlon</surname><given-names>JM</given-names></name><name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></name><name name-style="western"><surname>Thacker</surname><given-names>LR</given-names></name><name name-style="western"><surname>Heuman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Smith</surname><given-names>S</given-names></name><etal/></person-group>. <article-title>Linkage of gut microbiome with cognition in hepatic encephalopathy</article-title>. <source>Am J Physiol Gastrointest Liver Physiol</source> (<year>2012</year>) <volume>302</volume>:<page-range>G168&#8211;75</page-range>. doi: <pub-id pub-id-type="doi">10.1152/ajpgi.00190.2011</pub-id><pub-id pub-id-type="pmcid">PMC3345956</pub-id><pub-id pub-id-type="pmid">21940902</pub-id></mixed-citation></ref><ref id="B129"><label>129</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Merli</surname><given-names>M</given-names></name><name name-style="western"><surname>Lucidi</surname><given-names>C</given-names></name><name name-style="western"><surname>Pentassuglio</surname><given-names>I</given-names></name><name name-style="western"><surname>Giannelli</surname><given-names>V</given-names></name><name name-style="western"><surname>Giusto</surname><given-names>M</given-names></name><name name-style="western"><surname>Di Gregorio</surname><given-names>V</given-names></name><etal/></person-group>. <article-title>Increased risk of cognitive impairment in cirrhotic patients with bacterial infections</article-title>. <source>J Hepatol</source> (<year>2013</year>) <volume>59</volume>:<page-range>243&#8211;50</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2013.03.012</pub-id><pub-id pub-id-type="pmid">23523580</pub-id></mixed-citation></ref><ref id="B130"><label>130</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moratalla</surname><given-names>A</given-names></name><name name-style="western"><surname>Ampuero</surname><given-names>J</given-names></name><name name-style="western"><surname>Bellot</surname><given-names>P</given-names></name><name name-style="western"><surname>Gallego-Dur&#225;n</surname><given-names>R</given-names></name><name name-style="western"><surname>Zapater</surname><given-names>P</given-names></name><name name-style="western"><surname>Roger</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Lactulose reduces bacterial DNA translocation, which worsens neurocognitive shape in cirrhotic patients with minimal hepatic encephalopathy</article-title>. <source>Liver Int</source> (<year>2017</year>) <volume>37</volume>:<page-range>212&#8211;23</page-range>. doi: <pub-id pub-id-type="doi">10.1111/liv.13200</pub-id><pub-id pub-id-type="pmid">27388776</pub-id></mixed-citation></ref><ref id="B131"><label>131</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Cipollini</surname><given-names>V</given-names></name><name name-style="western"><surname>Anrather</surname><given-names>J</given-names></name><name name-style="western"><surname>Orzi</surname><given-names>F</given-names></name><name name-style="western"><surname>Iadecola</surname><given-names>C</given-names></name></person-group>. <article-title>Th17 and cognitive impairment: Possible mechanisms of action</article-title>. <source>Front Neuroanat</source> (<year>2019</year>) <volume>13</volume>:<elocation-id>95</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.3389/fnana.2019.00095</pub-id><pub-id pub-id-type="pmid">31803028</pub-id><pub-id pub-id-type="pmcid">PMC6877481</pub-id></mixed-citation></ref><ref id="B132"><label>132</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moreau</surname><given-names>R</given-names></name><name name-style="western"><surname>Elkrief</surname><given-names>L</given-names></name><name name-style="western"><surname>Bureau</surname><given-names>C</given-names></name><name name-style="western"><surname>Perarnau</surname><given-names>JM</given-names></name><name name-style="western"><surname>Th&#233;venot</surname><given-names>T</given-names></name><name name-style="western"><surname>Saliba</surname><given-names>F</given-names></name><etal/></person-group>. <article-title>Effects of long-term norfloxacin therapy in patients with advanced cirrhosis</article-title>. <source>Gastroenterology</source> (<year>2018</year>) <volume>155</volume>:<fpage>1816</fpage>&#8211;<lpage>1827 e9</lpage>. doi:&#160;<pub-id pub-id-type="doi">10.1053/j.gastro.2018.08.026</pub-id><pub-id pub-id-type="pmid">30144431</pub-id></mixed-citation></ref><ref id="B133"><label>133</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><collab>European Association for the Study of the Liver</collab></person-group>. <article-title>Electronic address eee, European association for the study of the l. EASL clinical practice guidelines for the management of patients with decompensated cirrhosis</article-title>. <source>J Hepatol</source> (<year>2018</year>) <volume>69</volume>:<page-range>406&#8211;60</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2018.03.024</pub-id><pub-id pub-id-type="pmid">29653741</pub-id></mixed-citation></ref><ref id="B134"><label>134</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><name name-style="western"><surname>Heuman</surname><given-names>DM</given-names></name><name name-style="western"><surname>Sanyal</surname><given-names>AJ</given-names></name><name name-style="western"><surname>Hylemon</surname><given-names>PB</given-names></name><name name-style="western"><surname>Sterling</surname><given-names>RK</given-names></name><name name-style="western"><surname>Stravitz</surname><given-names>RT</given-names></name><etal/></person-group>. <article-title>Modulation of the metabiome by rifaximin in patients with cirrhosis and minimal hepatic encephalopathy</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>:<elocation-id>e60042</elocation-id>. doi:&#160;<pub-id pub-id-type="doi">10.1371/journal.pone.0060042</pub-id><pub-id pub-id-type="pmid">23565181</pub-id><pub-id pub-id-type="pmcid">PMC3615021</pub-id></mixed-citation></ref><ref id="B135"><label>135</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Patel</surname><given-names>VC</given-names></name><name name-style="western"><surname>Lee</surname><given-names>S</given-names></name><name name-style="western"><surname>McPhail</surname><given-names>MJW</given-names></name><name name-style="western"><surname>Da Silva</surname><given-names>K</given-names></name><name name-style="western"><surname>Guilly</surname><given-names>S</given-names></name><name name-style="western"><surname>Zamalloa</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Rifaximin-alpha reduces gut-derived inflammation and mucin degradation in cirrhosis and encephalopathy: RIFSYS randomised controlled trial</article-title>. <source>J Hepatol</source> (<year>2022</year>) <volume>76</volume>:<page-range>332&#8211;42</page-range>. doi:&#160;<pub-id pub-id-type="doi">10.1016/j.jhep.2021.09.010</pub-id><pub-id pub-id-type="pmid">34571050</pub-id></mixed-citation></ref><ref id="B136"><label>136</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Fernandez</surname><given-names>J</given-names></name><name name-style="western"><surname>Piano</surname><given-names>S</given-names></name><name name-style="western"><surname>Bartoletti</surname><given-names>M</given-names></name><name name-style="western"><surname>Wey</surname><given-names>EQ</given-names></name></person-group>. <article-title>Management of bacterial and fungal infections in cirrhosis: The MDRO challenge</article-title>. <source>J Hepatol</source> (<year>2021</year>) <volume>75</volume>(<issue>Suppl 1</issue>):<page-range>S101&#8211;17</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2020.11.010</pub-id><pub-id pub-id-type="pmid">34039482</pub-id></mixed-citation></ref><ref id="B137"><label>137</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moratalla</surname><given-names>A</given-names></name><name name-style="western"><surname>Gomez-Hurtado</surname><given-names>I</given-names></name><name name-style="western"><surname>Santacruz</surname><given-names>A</given-names></name><name name-style="western"><surname>Moya</surname><given-names>&#193;</given-names></name><name name-style="western"><surname>Peir&#243;</surname><given-names>G</given-names></name><name name-style="western"><surname>Zapater</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>Protective effect of bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis</article-title>. <source>Liver Int</source> (<year>2014</year>) <volume>34</volume>:<page-range>850&#8211;8</page-range>. doi: <pub-id pub-id-type="doi">10.1111/liv.12380</pub-id><pub-id pub-id-type="pmid">24267920</pub-id></mixed-citation></ref><ref id="B138"><label>138</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moratalla</surname><given-names>A</given-names></name><name name-style="western"><surname>Gomez-Hurtado</surname><given-names>I</given-names></name><name name-style="western"><surname>Moya-Perez</surname><given-names>A</given-names></name><name name-style="western"><surname>Zapater</surname><given-names>P</given-names></name><name name-style="western"><surname>Peir&#243;</surname><given-names>G</given-names></name><name name-style="western"><surname>Gonz&#225;lez-Navajas</surname><given-names>JM</given-names></name><etal/></person-group>. <article-title>Bifidobacterium pseudocatenulatum CECT7765 promotes a TLR2-dependent anti-inflammatory response in intestinal lymphocytes from mice with cirrhosis</article-title>. <source>Eur J Nutr</source> (<year>2016</year>) <volume>55</volume>:<fpage>197</fpage>&#8211;<lpage>206</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s00394-015-0837-x</pub-id><pub-id pub-id-type="pmid">25657013</pub-id></mixed-citation></ref><ref id="B139"><label>139</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Moratalla</surname><given-names>A</given-names></name><name name-style="western"><surname>Caparros</surname><given-names>E</given-names></name><name name-style="western"><surname>Juanola</surname><given-names>O</given-names></name><name name-style="western"><surname>Portune</surname><given-names>K</given-names></name><name name-style="western"><surname>Puig-Kr&#246;ger</surname><given-names>A</given-names></name><name name-style="western"><surname>Estrada-Capetillo</surname><given-names>L</given-names></name><etal/></person-group>. <article-title>Bifidobacterium pseudocatenulatum CECT7765 induces an M2 anti-inflammatory transition in macrophages from patients with cirrhosis</article-title>. <source>J Hepatol</source> (<year>2016</year>) <volume>64</volume>:<page-range>135&#8211;45</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2015.08.020</pub-id><pub-id pub-id-type="pmid">26334579</pub-id></mixed-citation></ref><ref id="B140"><label>140</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Chen</surname><given-names>RC</given-names></name><name name-style="western"><surname>Xu</surname><given-names>LM</given-names></name><name name-style="western"><surname>Du</surname><given-names>SJ</given-names></name><name name-style="western"><surname>Huang</surname><given-names>SS</given-names></name><name name-style="western"><surname>Wu</surname><given-names>H</given-names></name><name name-style="western"><surname>Dong</surname><given-names>JJ</given-names></name><etal/></person-group>. <article-title>Lactobacillus rhamnosus GG supernatant promotes intestinal barrier function, balances treg and TH17 cells and ameliorates hepatic injury in a mouse model of chronic-binge alcohol feeding</article-title>. <source>Toxicol Lett</source> (<year>2016</year>) <volume>241</volume>:<page-range>103&#8211;10</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.toxlet.2015.11.019</pub-id><pub-id pub-id-type="pmid">26617183</pub-id></mixed-citation></ref><ref id="B141"><label>141</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bull-Otterson</surname><given-names>L</given-names></name><name name-style="western"><surname>Feng</surname><given-names>W</given-names></name><name name-style="western"><surname>Kirpich</surname><given-names>I</given-names></name><name name-style="western"><surname>Wang</surname><given-names>Y</given-names></name><name name-style="western"><surname>Qin</surname><given-names>X</given-names></name><name name-style="western"><surname>Liu</surname><given-names>Y</given-names></name><etal/></person-group>. <article-title>Metagenomic analyses of alcohol induced pathogenic alterations in the intestinal microbiome and the effect of lactobacillus rhamnosus GG treatment</article-title>. <source>PloS One</source> (<year>2013</year>) <volume>8</volume>:<elocation-id>e53028</elocation-id>. doi: <pub-id pub-id-type="doi">10.1371/journal.pone.0053028</pub-id><pub-id pub-id-type="pmid">23326376</pub-id><pub-id pub-id-type="pmcid">PMC3541399</pub-id></mixed-citation></ref><ref id="B142"><label>142</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Horvath</surname><given-names>A</given-names></name><name name-style="western"><surname>Leber</surname><given-names>B</given-names></name><name name-style="western"><surname>Schmerboeck</surname><given-names>B</given-names></name><name name-style="western"><surname>Tawdrous</surname><given-names>M</given-names></name><name name-style="western"><surname>Zettel</surname><given-names>G</given-names></name><name name-style="western"><surname>Hartl</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Randomised clinical trial: the effects of a multispecies probiotic vs. placebo on innate immune function, bacterial translocation and gut permeability in patients with cirrhosis</article-title>. <source>Aliment Pharmacol Ther</source> (<year>2016</year>) <volume>44</volume>:<page-range>926&#8211;35</page-range>. doi: <pub-id pub-id-type="doi">10.1111/apt.13788</pub-id><pub-id pub-id-type="pmcid">PMC5053220</pub-id><pub-id pub-id-type="pmid">27593544</pub-id></mixed-citation></ref><ref id="B143"><label>143</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><name name-style="western"><surname>Idilman</surname><given-names>R</given-names></name><name name-style="western"><surname>Mabudian</surname><given-names>L</given-names></name><name name-style="western"><surname>Hood</surname><given-names>M</given-names></name><name name-style="western"><surname>Fagan</surname><given-names>A</given-names></name><name name-style="western"><surname>Turan</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Diet affects gut microbiota and modulates hospitalization risk differentially in an international cirrhosis cohort</article-title>. <source>Hepatology</source> (<year>2018</year>) <volume>68</volume>:<page-range>234&#8211;47</page-range>. doi: <pub-id pub-id-type="doi">10.1002/hep.29791</pub-id><pub-id pub-id-type="pmid">29350768</pub-id></mixed-citation></ref><ref id="B144"><label>144</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Macnaughtan</surname><given-names>J</given-names></name><name name-style="western"><surname>Albillos</surname><given-names>A</given-names></name><name name-style="western"><surname>Kerbert</surname><given-names>A</given-names></name><name name-style="western"><surname>Vargas</surname><given-names>V</given-names></name><name name-style="western"><surname>Durand</surname><given-names>F</given-names></name><name name-style="western"><surname>Gines</surname><given-names>P</given-names></name><etal/></person-group>. <article-title>O09 a double blind, randomised, placebo-controlled study to assess safety and tolerability of oral enterosorbent carbalive (Yaq-001) in cirrhotic patients</article-title>. <source>Gut</source> (<year>2021</year>) <volume>70</volume>:<page-range>A5&#8211;6</page-range>. doi: <pub-id pub-id-type="doi">10.1136/gutjnl-2021-BASL.9</pub-id></mixed-citation></ref><ref id="B145"><label>145</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Bajaj</surname><given-names>JS</given-names></name><name name-style="western"><surname>Khoruts</surname><given-names>A</given-names></name></person-group>. <article-title>Microbiota changes and intestinal microbiota transplantation in liver diseases and cirrhosis</article-title>. <source>J Hepatol</source> (<year>2020</year>) <volume>72</volume>:<page-range>1003&#8211;27</page-range>. doi: <pub-id pub-id-type="doi">10.1016/j.jhep.2020.01.017</pub-id><pub-id pub-id-type="pmid">32004593</pub-id></mixed-citation></ref><ref id="B146"><label>146</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Maran</surname><given-names>RR</given-names></name><name name-style="western"><surname>Thomas</surname><given-names>A</given-names></name><name name-style="western"><surname>Roth</surname><given-names>M</given-names></name><name name-style="western"><surname>Sheng</surname><given-names>Z</given-names></name><name name-style="western"><surname>Esterly</surname><given-names>N</given-names></name><name name-style="western"><surname>Pinson</surname><given-names>D</given-names></name><etal/></person-group>. <article-title>Farnesoid X receptor deficiency in mice leads to increased intestinal epithelial cell proliferation and tumor development</article-title>. <source>J Pharmacol Exp Ther</source> (<year>2009</year>) <volume>328</volume>:<page-range>469&#8211;77</page-range>. doi: <pub-id pub-id-type="doi">10.1124/jpet.108.145409</pub-id><pub-id pub-id-type="pmcid">PMC2682273</pub-id><pub-id pub-id-type="pmid">18981289</pub-id></mixed-citation></ref><ref id="B147"><label>147</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><name name-style="western"><surname>Xiang</surname><given-names>X</given-names></name><name name-style="western"><surname>Hwang</surname><given-names>S</given-names></name><name name-style="western"><surname>Feng</surname><given-names>D</given-names></name><name name-style="western"><surname>Shah</surname><given-names>VH</given-names></name><name name-style="western"><surname>Gao</surname><given-names>B</given-names></name></person-group>. <article-title>Interleukin-22 in alcoholic hepatitis and beyond</article-title>. <source>Hepatol Int</source> (<year>2020</year>) <volume>14</volume>:<page-range>667&#8211;76</page-range>. doi: <pub-id pub-id-type="doi">10.1007/s12072-020-10082-6</pub-id><pub-id pub-id-type="pmcid">PMC7572732</pub-id><pub-id pub-id-type="pmid">32892258</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>